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Antigen-specific immune modulation using an injectable biomaterial 
 
Abstract 
 
The  field  of  immunology  has  advanced  tremendously  over  the  last  40  years,  with 
seminal  findings  that  have  guided  the  development  of  powerful  new  therapies.  
However,  the  ability  to  induce  safe  and  long-lasting  antigen-specific  tolerance  has 
remained elusive.  A therapy that could prevent the immune system from aberrantly 
destroying self-tissues, without impairing its capacity to eliminate dangerous pathogens, 
would be transformative for the treatment of autoimmune diseases.  In addition, such a 
therapy  could  also  greatly  advance  the  field  of  organ  transplantation  by  inducing 
antigen-specific tolerance to prevent graft rejection. 
 
In this thesis, the overarching goal was to develop a biomaterial delivery system that 
could recruit and program antigen presenting cells, specifically dendritic cells (DCs), in 
a non-inflammatory environment, allowing them to orchestrate downstream immune 
responses that are both antigen-specific and tolerogenic.  Gold nanoparticles (AuNPs) 
were  used  to  deliver a  DC  recruitment  factor,  GM-CSF,  from  an  injectable  alginate 
based hydrogel.  Both the release of GM-CSF and the physical porous structure of the 
gel were tuned to achieve effective recruitment of a highly enriched population of DCs.  
The ability of this system to generate downstream antigen-specific responses in T cells 
was demonstrated in a mouse model of type 1 diabetes (T1D).  Additionally, the DCs iv 
 
recruited in this system were characterized and found to exhibit features that would 
make them competent to induce tolerance.  Finally, a new method was developed for 
localized delivery and cell-triggered release of a peptide antigen from the material.  
Over time, antigen-specific T cells expressing FoxP3, a marker of regulatory T cells, which 
are  key  mediators  of  immune  tolerance,  accumulated  in  the  gels.    Together,  these 
findings  demonstrate  that  it  is  possible  to  recruit  and  program  DCs  in  a  non-
inflammatory context, and  that these  DCs can  induce  downstream antigen-specific 
responses.  These promising results suggest that this system may be able to  promote 
tolerance in the setting of autoimmune disease. 
 
This thesis advances the field of immunomodulatory biomaterials by introducing new 
methodologies  for  precisely  recruiting  and  manipulating  DCs  in  a  non-inflammatory 
context.  This work may provide the basis for further development of a highly effective 
and therapeutic antigen-specific tolerogenic vaccine. 
 
   v 
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Savoir s'étonner à propos est le premier pas fait sur la route de la découverte. 
 
(Knowing how to be astonished is the first step taken on the road of discovery.) 
 
–Louis Pasteur1 
 
Chapter 1. Introduction 
 
1.1 Background and Motivation 
 
The human immune system defends the body from a constant barrage of pathogens in 
the environment.  Immune cells traffic systemically and are found in almost every tissue 
in the body, forming an incredibly complex and evolving network.  A large number of 
diseases  and  disorders  are  caused  by  dysfunctional  immune  responses.    Infectious 
diseases take hold when the immune system fails to be adequately or rapidly activated.  
Recently,  cancer  has  increasingly  been  viewed  through  the  lens  of  immunology,  in 
terms of a tumor’s ability to evade elimination by the immune system1–3.  On the other 
end  of  the  spectrum,  excessive  or  misdirected  immune  responses  are  the  cause  of 
chronic  inflammation,  autoimmune  diseases,  and  allergies.    The  rejection  of  organ 
transplants,  though  not  technically  a  disease,  is  another  area  in  which  immune 
activation  is  undesirable4.    In  addition,  new  research  is  revealing  that  many  other 
diseases,  such  as  Alzheimer’s5,  narcolepsy6,  and  epilepsy7,  have  an  important 
immunological component.  There is also a growing appreciation for the capacity of 
immune cells to alter or direct a variety of processes in development, homeostasis, and 
repair, such as angiogenesis8,9, wound healing10,11, and bone remodeling12–14. 
 
Vaccination can be considered as one of the most impactful medical advances in 
history.  It has led to the eradication of smallpox, as well as the elimination of polio, 
measles,  and  tetanus  in  much  of  the  world,  greatly  extending  the  average  life 
expectancy15.    However,  until  recently,  vaccine  development  has  been  largely 2 
 
empirical,  and  there  remain  are  a  number  of  critical  areas  in  which  effective 
vaccination is not possible15,16.  Pathogens that mutate rapidly, such as retroviruses, are 
inherently  elusive  targets17,18,  and  tumors  develop  mechanisms  for  evading  immune 
surveillance2.    Of  particular  interest  here,  tolerogenic  vaccination  to  treat  immune 
diseases or prevent transplant rejection has not been possible yet19,20.  Over the last 40 
years,  the  field  of  immunology  has  flourished  with  seminal  findings  such  as  the 
elucidation of the molecular structure and function of major histocompatibility complex 
(MHC)  molecules21,  the  discovery  of  Toll-like  receptor  (TLR)  ligands,  and  the 
identification of different cell types such as dendritic cells (DCs)22 and regulatory T cells 
(Tregs)23,24.  With these advances comes an increased ability to manipulate the immune 
system by developing and designing new therapies in a rational way. 
 
This thesis explores the  possibility of developing  a  materials-based vaccine  that can 
control  immune  responses  towards  defined  antigens  in  a  non-inflammatory 
environment, with the goal of inducing tolerance. 
 
DCs and T cells in autoimmunity 
 
Autoimmune diseases represent a significant burden on society.  It was estimated that 
autoimmune  diseases  affect  ~5-8%  of  the  population  in  the  United  States,  with 
treatments costing around $100 billion each year in the US, as estimated recently by the 
NIH25.  Aside from the economic impact, autoimmune diseases take a serious toll on 
patients  as  well  as  on  affected  families.    Autoimmune  diseases  arise  when  the 
breakdown  of  multiple  barriers  results  in  a  loss  of  tolerance  towards  self-antigens.  3 
 
Autoimmune  diseases  are  complex  and  multifactorial,  involving  a  combination  of 
genetic predispositions and largely uncharacterized environmental factors.   
 
The adaptive branch of the immune system comprises highly specialized cells, known as 
B and T cells, which mount antigen-specific immune responses and acquire long term 
immunological memory.  The B cell receptors (BCRs) and T cell receptors (TCRs) that 
mediate the recognition of antigen are generated through an elegant combinatorial 
mechanism, known as VDJ recombination.  The number of unique TCRs represented in 
one individual is estimated to be approximately 107 – 108, which is a fraction of the ~1016 
possible T cell receptors that can theoretically be generated26.  This staggering diversity 
of receptors endows the immune system with the ability to effectively protect its host 
from a huge range of unknown pathogens, some of which may have never previously 
been encountered in the history of evolution.  Stochastically, some of the receptors 
generated  will  recognize  self-antigens,  and  cells  cannot  intrinsically  distinguish  self-
antigens from foreign antigens.  Consequently, there are several mechanisms in place 
to prevent aberrant destruction of self-tissues.  In central tolerance, B and T cells with a 
high affinity for self-antigens are eliminated by deletion in the thymus.  However, some 
weakly or moderately self-reactive cells escape, even in healthy individuals27. 
 
Several tightly regulated mechanisms of peripheral tolerance keep these auto-reactive 
cells in check  and maintain  tolerance  to self-tissues.  The  most basic mechanism of 
peripheral tolerance is termed immunological ignorance, which reflects the fact that 
the immune system has limited access to many self-antigens because they are located 
either in intracellular compartments or in immunologically privileged tissues, such as the 4 
 
eyes  or  brain.    The  next  level  of  peripheral  tolerance  encompasses  the  cell  intrinsic 
signaling networks that control T cell activation, proliferation, and effector functions.  To 
be  effectively  activated,  T  cells  need  to  receive  “signal  1”  from  TCR  binding  to  its 
cognate  antigen  presented  by  MHC,  together  with  “signal  2”  from  costimulatory 
molecule signaling through CD28.  “Signal 3”, which is provided by soluble cytokines, 
controls the polarization of T cells28.  In the absence of inflammation, self-reactive T cells 
that encounter their cognate antigen will receive signal 1 from antigen presenting cells 
(APCs) in the absence of signal 2, leading to unresponsiveness, or anergy28,29.  Inhibitory 
molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-
1  (PD-1)  are  also  integrated  into  this  signaling  network  and  mediate  negative 
costimulatory  signals  that  are  critical  for  maintaining  peripheral  tolerance  and  for 
resolving  inflammation  after  the  clearance  of  a  pathogen30,31.    The  highest  level  of 
regulation in peripheral tolerance is sometimes called “dominant suppression”, since it is 
mediated  by  specialized  regulatory  cells  that  can  suppress  the  responses  of  other 
effector  cells,  including  ones  that  recognize  a  different  antigen.    In  particular, 
regulatory  T  cells  (Tregs)  are  critical  for  maintaining  peripheral  tolerance32,33.    CD4+ 
FoxP3+ natural Tregs (nTregs) are generated during thymic selection34.  A deficiency in 
Tregs arising from defects in the foxp3 gene results in multi-organ autoimmunity in mice 
(“scurfy”) and humans (IPEX)33.  Tregs exert their suppressive functions both on DCs and 
on effector T cells through a combination of contact-mediated signals and secreted 
cytokines33.    More  recently,  other  CD4+  T  cells  with  regulatory  capacity  have  been 
described, such as adaptive Tregs34 or IL-10 producing Tr1 cells, which can be identified 
based on co-expression of the surface markers LAG-3 and CD49b35.  In addition, there is 5 
 
a  growing  body  of  research  about  CD8+  Tregs36,37,  regulatory  B  cells38,39,  and  other 
suppressive innate cells40. 
 
For autoimmune disease to arise, several of these barriers need to become disrupted or 
deregulated.  The initial events triggering autoimmunity are still not well understood.  It is 
generally  thought  that  disease  processes  are  initiated  following  tissue  damage  or 
infection, and multiple insults to the tissue may occur before tolerance is broken and 
autoimmunity develops41.  Naturally occurring waves of cell death or remodeling that 
occur during development could be implicated42 because of the release of damage 
associated molecular patents (DAMPs) and intracellular antigens that are normally not 
accessible to immune cells.  Infection of a tissue also leads to the release of intracellular 
antigens, as well as epitope spreading to self-antigens.  The theory of molecular mimicry, 
which holds that self-tolerance is broken following infection by a pathogen expressing 
antigens  that  closely  mimic  self-antigens,  has  not  been  definitively  proven  in  the 
context  of  human  disease43.    Finally,  even  though  there  is  strong  evidence  that 
environmental  factors  other  than  pathogens  have  a  strong  impact  on  the 
development  of  autoimmunity,  these  factors  are  still  largely  uncharacterized.    One 
promising  area  of  research  investigates  the  role  of  the  microbiome  in  shaping  the 
immune system in ways that may promote or suppress autoimmunity44,45. 
 
Dendritic  cells  (DCs)  play  a  central  role  in  establishing  and  maintaining  peripheral 
tolerance.  DCs bridge the innate and adaptive branches of the immune system, and 
orchestrate  the  downstream  responses  of  the  adaptive  immune  response  (Fig.  1.1).  
DCs constantly patrol almost every tissue in the body to monitor them for invasion by 6 
 
pathogens.  In steady-state conditions, cell debris from normal cell turnover constitutes 
the  main source  of antigens46.  In the  absence  of inflammatory signals, DCs induce 
anergy and deletion of autoreactive T cells28,29,46.  Since DCs direct the differentiation or 
polarization of effector T cells, they can also induce phenotypic skewing away from Th1 
or  Th17  subsets,  which  mediate  autoimmunity.    DCs  also  interact  with  different 
regulatory cell types47, triggering the activation or expansion of natural Tregs, or the 
induction of Tr1 cells. 
 
 
Figure 1.1.  The interplay of dendritic cells and T cells in tolerance and immunity.  DCs 
integrate  signals  from  the  environment  and  direct  downstream  T  cell  responses.  
Regulatory T cells have the capacity to suppress both inflammatory DCs and effector T 
cells, which is critical for the resolution of inflammation after a pathogen is cleared as 
well as for maintaining tolerance towards self-tissues in steady state conditions. 
 
DCs are very heterogeneous and can be subdivided into conventional DCs (cDCs), 
Langerhans  cells,  plasmacytoid  DCs  (pDCs),  and  monocyte-derived  DCs48  (Fig.  1.2).  
cDCs,  which  predominate  in  steady-state  conditions,  arise  from  a  bone  marrow 7 
 
precursor  cell.    cDCs  can  be  further  subdivided  into  migratory  DCs  that  reside  in 
peripheral tissues and migrate to lymph nodes (LNs), and lymphoid-resident DCs that 
differentiate and remain in lymphoid organs, i.e. the lymph nodes, spleen, and thymus.  
Langerhans cells are tissue-resident DCs found in the skin, and, while they exert similar 
functions  as  migratory  DCs,  they  are  derived  from  a  specialized  precursor  cell 
population that resides in the skin.  pDCs are characterized by their ability to secrete 
large  amounts  of  type  I  interferons  (IFNs),  making  them  particularly  effective  at 
eliminating  viral  infections.    Finally,  monocyte-derived  DCs  are  believed  to  be  a 
reservoir of APCs that arise in settings of inflammation from circulating blood monocytes 
that differentiate to acquire prototypical DC features similar to cDCs, including CD11c 
and MHCII expression, as well as potent antigen-presenting capacity.  Within each of 
these four main DC subsets, there are many further subdivisions based on the expression 
of different cell surface markers.  Adding to this staggering complexity, DCs are plastic, 
and  the  surface  marker  expression  of  DCs  can  vary  depending  on  their  tissue 
localization and their level of differentiation or maturation.  It has been proposed that 
certain types of DCs, such as mucosal DCs49,50 or Langerhans cells51, may be specialized 
for inducing regulatory responses, but there is no consensus in the field52.  Reports in the 
literature show that many different DC subsets, including conventional (or myeloid) and 
plasmacytoid DCs, play a role in inducing or maintaining tolerance28,52. 8 
 
 
Figure 1.2.  Differentiation and tissue localization of different DC subsets.  Adapted from 
Belz and Nutt48. 
 
Current strategies for treating autoimmune diseases 
 
Immunosuppressive  drugs  can  dampen  immune  responses  and  alleviate  the 
destruction  of  self-tissues  by  autoreactive  immune  cells.    However,  broad 
immunosuppression  has  serious  consequences  on  the  long-term  health  of  patients, 9 
 
making them prone to deadly infections.  In the setting of type 1 diabetes, cyclosporin 
A  was  shown  to  preserve  beta  cell  function,  allowing  many  patients  to  live  insulin-
independent for prolonged periods; however, the treatment caused accelerated renal 
dysfunction, and the protective effect did not last after cessation of the treatment53.  
This  ratio  of  risk  to  benefit  is  not  acceptable,  particularly  for  a  disease  like  type  1 
diabetes  that  occurs  in  young  patients.    By  the  same  token,  autologous  HSC 
transplantation, while it was found to be effective in resetting the immune system and 
achieving long-term benefits in patients  with severe  autoimmunity, is currently not  a 
sufficiently safe treatment to be suitable for widespread use19. 
 
Immunomodulatory  therapies  targeting  immune  receptors  or  cytokines  represent  a 
slightly more targeted approach to treating autoimmune diseases, and, as a result, they 
should be associated with fewer risks than generalized immunosuppression.  Therapies 
such  as  CTLA4-Ig  (abatacept),  anti-CD20  (rituximab),  and  anti-CD3 
(teplizumab/otelixizumab) generated great interest and have been tested in clinical 
trials recently53.  These treatments are not necessarily viable as long-term treatments, 
since chronic depletion of B or T cells with anti-CD20 or anti-CD3, respectively, carries 
serious risks, and chronic costimulatory blockade with CTLA4-Ig may increase the risk of 
infections and cancer.  Instead, the hope is that a short course of treatment could 
confer  longer-term  tolerance  by  interrupting  destructive  signaling  pathways  or  by 
enhancing the regulatory capacity of Tregs.  Since B cells play an important role as 
APCs, in addition to producing pathogenic autoantibodies, B  cell depletion can be 
effective even in autoimmune disease that are primarily T cell driven.  Depleting B cells 
reduced disease in preclinical models of T1D and MS, and promising initial results are 10 
 
emerging  from in clinical trials  for  RA,  MS,  and  T1D19.  On the  other hand, anti-CD3 
therapy, which garnered high hopes based on preclinical studies showing reversal of 
diabetes  in  several  T1D  models53  and  amelioration  of  EAE19,  has  seen  disappointing 
results  in  clinical  trials.    Second-generation,  non  FcR  binding  anti-CD3  is  thought  to 
function by preferentially inducing deletion and anergy of effector T cells, shifting the 
ratio of Teffs : Tregs.  Unfortunately, two large phase 3 trials recently failed to meet their 
primary endpoints19,53, even though one of the studies in newly-diagnosed T1D patients 
did initially show some beneficial effects that lasted well beyond the short course of 
treatment, but were not maintained.  A number of trials are still ongoing to continue 
testing anti-CD3 in a number of different diseases, including T1D.  Low dose IL-2 therapy 
is another example of an immunomodulatory therapy that has not performed up to 
expectations  in  clinical  trials.    This  treatment  was  designed  to  preferentially  expand 
Tregs,  which  express  the  high-affinity IL-2  receptor,  as  well  as  correct  defects  in IL-2 
signaling in Tregs that are seen in some T1D patients19.  This approach did not work well 
in new-onset diabetic patients because NK cells were dramatically expanded19.  These 
recent disappointments highlight the some of the challenges in translating preclinical 
findings, which are due in part to inter-species differences between the mouse and 
human immune systems.   
 
An  entirely  different  strategy  for  treating  autoimmune  diseases  involves  cell-based 
therapies.    Dendritic  cell  based  therapies  were  pioneered  in  the  setting  of  cancer 
vaccination, with the  first clinical study of a  dendritic cell  (DC)  vaccine  reported in 
199654 and the first therapeutic cancer vaccine, Provenge, approved by the FDA in 
201055.    Today,  DC-based  cancer  vaccines  are  an  increasingly  active  area  of 11 
 
investigation,  with  many  current  efforts  targeting  melanoma.    In  the  context  of 
autoimmune diseases, a number of pre-clinical models have shown that administration 
of Tregs or tolerogenic DCs has the potential to delay or prevent disease, and, in some 
cases,  reverse  new-onset  disease56.    There  are  currently  several  clinical  trials 
investigating the safety of Tregs57 and tolerogenic DCs58,59 in humans.  Mesenchymal 
stromal cells (MSCs) have also been found to exhibit immunomodulatory properties and 
could have therapeutic effects in autoimmune diseases19. 
 
Despite a promising outlook in terms of therapeutic potential, the significant cost and 
complexity associated with cell-based therapies makes them challenging to take into 
the clinic.  Tolerogenic cell therapies face a particularly large hurdle since the cells of 
interest,  i.e.  tolerogenic  DCs,  Tregs,  and  particularly  antigen-specific  Tregs,  are  rare, 
requiring autologous cells to be expanded ex vivo before they can be clinically useful60.  
Contamination with undesired cell populations, such as effector T cells, poses a serious 
safety  concern  that  may  need  to  be  addressed  by  including  additional  sorting  or 
purification steps before the cells can be re-administered to patients60.  Each of these 
additional  manipulations  complicates  the  regulatory  path  and  adds  to  the  high 
personnel and facility costs for manufacturing such therapies.  Only adding to these 
issues, it has been  found that the  majority of cells die  upon administration or fail to 
home to the target tissue.  For instance, a study in melanoma patients showed that <2% 
of intradermally injected, mature DCs migrated to the draining lymph nodes, and that 
the homing efficiency was even lower, only <0.5%, for immature DCs61.  The stability of 
the cell phenotype after transplantation is also a concern, particularly for therapies that 
involve in vitro conditioning using bioactive factors or drugs. 12 
 
 
Materials based vaccines for immune modulation 
 
An  ever-increasing  understanding  of  the  mechanisms  controlling  immunity  and 
tolerance  is  laying  the  ground  for  the  design  of  novel  therapeutic  strategies.    An 
exciting and rapidly growing area of research at the intersection of immunology and 
bioengineering involves the use of materials to exert specific and powerful control over 
immune responses.  Several efforts aim to increase the efficacy of vaccines by using 
materials to coordinate antigen and danger signal delivery, either by controlling their 
spatio-temporal presentation or by physically coupling them16,62.  Further, the material 
carriers  themselves  can  be  designed  to  act  as  adjuvants  or  present  adjuvants  in  a 
manner  that  makes  them  more  effective16.    There  are  several  biomaterials-based 
particle  vaccines  currently  under  commercial  development,  most  of  which  target 
infectious diseases16. 
 
In the area of cancer immunotherapy, Hori et al. have shown that hydrogels made of 
alginate,  a  naturally  occurring  polysaccharide,  can  be  used  to  deliver  DCs  or 
immunostimulatory cytokines to the immediate vicinity of melanoma tumors in the skin.  
The  delivery  of  either  DCs  or  appropriate  bioactive  factors  both  showed  promising 
results,  including  enhanced  leukocyte  infiltration  into  the  tumors,  control  of  tumor 
growth, and increased survival63.  In a different approach, Ali et al. devised an elegant 
strategy  to  address  limitations  of  cell-based  therapies  by  using  a  porous  polymeric 
scaffold to recruit and program DCs directly in vivo.  The scaffold mimics a setting of 
infection  by  presenting  tumor  antigens  along  with  danger  signals  in  a  coordinated 13 
 
manner, thus eliciting anti-tumor responses mediated by DCs and cytotoxic T cells.  This 
materials-based  cancer  vaccine  was  shown  to  be  effective  in  mouse  models  of 
melanoma62,64 and glioblastoma65,66, and it is currently being investigated in a phase I 
safety study in melanoma patients67. 
 
In the area of immune tolerance, several noteworthy studies have been published in 
recent years.  Iron oxide nanoparticles presenting self-peptide MHC (pMHC) complexes 
were discovered to have the unexpected property of expanding a subset of memory 
CD8+ T cells with regulatory capacity.  These  regulatory CD8+  T cells were  found to 
suppress other T cells and  mediate  killing of autoantigen-presenting DCs,  leading  to 
therapeutic effects in a mouse model of T1D68.  Another interesting approach involved 
the use of gold nanoparticles to co-deliver a peptide antigen together with ITE, a small 
molecule aryl hydrocarbon receptor (AHR) ligand that was shown to act on both DCs 
and  T  cells69.    Co-delivery  of  a  disease-related  antigen  with  ITE  on  the  gold 
nanoparticles  was  found  to  ameliorate  disease  in  EAE,  a  mouse  model  of  MS,  by 
inducing  tolerogenic  DCs  and  increasing  the  numbers  of  CD4+  Tregs70.    Also  in  the 
setting of EAE, peptide-coupled polystyrene or PLGA particles were successfully used to 
induce tolerance in prophylactic and therapeutic settings71.  This work built on previous 
findings showing that EDCI-fixed, peptide-coupled apoptotic splenocytes could induce 
tolerance72.  The polymeric particles were used as mimics of apoptotic cells, making the 
strategy more appealing for potential use as a therapy both from both regulatory and 
manufacturing  standpoints.    The  size  and  delivery  route  leads  these  particles  to  be 
taken up by a specialized population of splenic macrophages, and therapeutic effects 
were attributed to both Treg activation, as well as T cell anergy71. 14 
 
 
Overall,  the  application  of  biomaterials  to  the  field  of  immunotherapy  has  great 
potential  to  yield  vaccines  with  increased  specificity,  efficacy,  and  potency.    In 
addition, it opens up new possibilities for developing a tolerogenic vaccine, which has 
not  been  possible  to  date  using  more  traditional  vaccination  strategies.    This  thesis 
attempted to address some of the challenges associated with cell-based tolerogenic 
therapies  by  using  a  material  to  program  DCs  for  tolerance  in  a  spatio-temporally 
controlled manner (Fig. 1.3). 
 
 
Figure  1.3.  A  biomaterial  can  be  designed  to  modulate  the  immune  system  in  an  
antigen-specific  manner.  A  delivery  system  releasing  bioactive  factors  in  a  spatio-
temporally  controlled  manner  could  be  used  to  recruit  DCs  into  the  material  and 
program them for tolerance.  After exposure to a defined peptide antigen in a non-
inflammatory environment, the DCs would be redeployed to the draining lymph nodes, 
where they could induce, expand, and/or activate antigen-specific regulatory T cells, 
which have the capacity to traffic systemically and control autoimmunity. 
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1.2 Hypothesis 
 
A non-inflammatory material system releasing defined recruitment and programming 
factors  can  orchestrate  the  recruitment  of  DCs  and  induce  antigen-specific  T  cell 
responses towards immune tolerance 
 
1.3 Specific Aims 
 
Three specific aims tested the above hypothesis: 
Aim  1:  Develop  a  non-inflammatory  alginate-based  material  system  to  effectively 
recruit DCs 
Aim  2:  Characterize  the  recruited  DCs  and  demonstrate  that  they  can  orchestrate 
antigen-specific T cell responses 
Aim 3: Conjugate a peptide antigen to alginate as a delivery strategy for generating 
antigen-specific tolerogenic responses in vivo 
 
1.4 Significance 
 
This work will expand the possible applications of biomaterials for immunomodulation 
and  take  steps  towards  the  development  of  an  effective  materials-based,  antigen-
specific tolerogenic vaccine.  The material delivery system described here builds on 
previous work to create a hydrogel that is non-inflammatory, can be administered in a 
minimally  invasive  manner,  and  effectively  recruits  DCs.    In  addition,  strategies  are 
explored for presenting defined peptide antigens to DCs in a highly localized manner, 16 
 
which could have important implications for achieving precise control over immune 
responses,  as  well  as  improving  the  safety  of  tolerogenic  therapies  involving  the 
administration of disease-associated antigens. 
 
The eventual goal is that such a material system could provide an alternative to cell-
based therapies involving ex vivo manipulations of autologous cells, some of which are 
currently  in  development  to  treat  autoimmunity.    The  ability  to  generate  antigen-
specific  tolerance  would  drastically  change  the  treatment  options  for  autoimmune 
diseases, as well as for transplantation tolerance. 
 
More generally, this line of work may provide tools to increase our understanding of the 
mechanisms controlling immunity and tolerance.  Biomaterials that serve as a privileged 
sites  for  the  infiltration  of  immune  cells  could  be  used  as  in  vivo  systems  to  study 
interactions between different cell types and explore the doses and kinetics of antigen 
presentation  that  are  required  to  establish,  or  re-establish,  immune  tolerance.    In 
addition, the knowledge that is gained may inform the design of other materials-based 
vaccines, in particular cancer vaccines, to avoid initiating autoimmune diseases as a 
side effect, which is a growing risk as these vaccines become increasingly potent. 
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Chapter  2.  A  non-inflammatory,  pore-forming  hydrogel  releasing  GM-CSF 
effectively recruits dendritic cells (DCs) in vivo 
 
2.1 Introduction 
 
Biomaterials based vaccines are a promising new class of technologies for modulating 
immune  responses  in  ways  that  have  previously  not  been  possible.    As  reviewed  in 
Chapter  1,  some  of  the  applications  being  pursued  include  raising  immunity  to 
eradicate tumors, as well as inducing tolerance towards the body’s own tissues to treat 
autoimmune  diseases1.    While  a  number  of  groups  are  developing  systemically 
delivered nanoparticle carriers to target particular cells or tissues2,3, another promising 
strategy involves the use of porous material scaffolds that immune cells can infiltrate 
and where they can be programmed by well-defined, localized cues4.  Using a scaffold 
to recruit and program immune cells in a localized manner is appealing for inducing 
tolerance,  since  systemic  delivery  of  a  disease-related  antigen  could  re-activate 
effector T cells and exacerbate disease5.  The scaffold system previously developed by 
Ali and colleagues as a cancer vaccine4 is made from poly-lactide-co-glyocolide (PLG), 
a material that is highly biocompatible, but that may induce some inflammation6,7.  In 
addition, surgical implantation is required to introduce this scaffold into the body.  These 
properties  are  not  problematic  for  applications  in  which  immunity  is  being  raised 
against tumors or pathogens, since the added inflammation may assist in activating the 
immune system.  However, for the induction of tolerance, even a moderate level of 
inflammation may run counter to the desired outcome.  A new material platform that is 
inherently  non-inflammatory  and  can  be  delivered  in  a  minimally  invasive  manner 24 
 
would expand the utility of materials based vaccines and make them more amenable 
for inducing tolerance.  This chapter addresses specific aim 1 of this thesis by describing 
the development and characterization of a non-inflammatory, injectable hydrogel that 
can effectively recruit DCs. 
 
The  material  selected  for  this  application  is  alginate,  a  highly  biocompatible,  non-
inflammatory  polysaccharide  composed  of  alternating  blocks  of  mannuronic  and 
guluronic acid.  This polymer is FDA-approved for use as an excipient, a wound dressing 
material8, and an additive to common food items.  In addition, alginate has been used 
as a cell carrier in a number of clinical trials without adverse effects9.  Reports in the 
literature concerning the immunogenicity of alginate are conflicting, but this is likely a 
reflection  of  the  fact  that  many  commercially  available  preparations  of  alginate 
contain a number of contaminants.  Studies performed using highly purified alginate 
show that the polymer does not induce immune cell activation9,10.  Alginate can be 
crosslinked  by  divalent  cations,  such  as  calcium,  to  form  an  ionically  crosslinked 
hydrogel9.  It is possible to chemically modify alginate in a variety of ways to impart it 
with different functionalities, such as degradability or cell adhesive properties9.  Alginate 
hydrogels are being used for a variety of applications, including therapeutic  in vivo 
delivery of single11,12 or dual13 growth factors, as well as in vivo cell delivery for tissue 
regeneration14,15.    One  limitation  of  standard  alginate  hydrogels  is  that  they  are 
nanoporous and do not allow cell infiltration or migration.  Several different techniques 
have been developed for fabricating alginate gels that contain macro-scale pores16–18.  
More recent innovations have resulted in macroporous scaffolds that can be delivered 
in a minimally invasive manner through a needle, following either covalent17 or ionic18 25 
 
crosslinking.  Ionically crosslinked macroporous gels can be obtained by incorporating 
rapidly degrading porogen beads into a bulk gel that will form pores in situ as they 
degrade.  Several different parameters can be varied to tune the size, elastic modulus, 
and  degradation  rate  of  the  porogens,  which  will  in  turn  alter  the  overall  structural 
properties of the pore-forming gels.  The composition of the alginate polymer used to 
fabricate  the  beads  controls  both  the  mechanical  properties  as  well  as  the 
degradation of the porogens.  Partial oxidation of alginate opens some of the sugar 
rings in the polysaccharide chain and creates hydrolytically labile bonds19,20.  However, 
this chemistry introduces aldehyde groups that can react with primary amines and non-
specifically bind proteins in vivo, which may cause some inflammation at high degrees 
of oxidation.  To address this issue, the aldehydes in oxidized alginate can be reduced 
to  yield  primary  alcohols,  while  still  allowing  hydrolytic  degradation  of  the  polymer.  
These pore-forming gels are permissive for cell migration and can be used as a cell 
delivery platform to disperse cells after implantation18.  Here, these gels are adapted to 
be  used  for  effective  recruitment  and  redeployment  of  DCs,  which  are  key 
orchestrators of immune responses, as discussed in Chapter 1. 
 
Since,  by  definition,  a  non-inflammatory  material  would  not  mediate  immune  cell 
infiltration  on  its  own,  a  bioactive  factor  would  be  required  to  recruit  DCs  into  the 
system.  Many chemokines and factors involved in lymphocyte recruitment have been 
extensively  studied.    One  such  biomolecule,  granulocyte-macrophage  colony 
stimulating factor (GM-CSF) is a potent factor for DC recruitment, differentiation, and 
proliferation.  GM-CSF is a small (14.2 kDa in mouse, 14.6 kDA in human) single-chain 
glycoprotein.    In  vitro,  GM-CSF  is  known  to  promote  DC  survival,  proliferation,  and 26 
 
differentiation.  GM-CSF is commonly used as a media supplement to generate DCs 
from precursors in bone marrow or peripheral blood, and the differentiated DCs remain 
immature in the absence of other inflammatory cytokines or TLR ligands.  It has also 
been  shown  to  induce  chemotaxis  and  chemokinesis  of  DCs  in  vitro,  confirming  its 
action as a recruitment factor21.  In vivo, GM-CSF is secreted by a number of different 
cell types22, including T cells, monocytes, and macrophages, as well as by other non-
immune  cells  such  as  fibroblasts  and  endothelial  cells.    Although  GM-CSF  is  used 
successfully in cell-based cancer vaccines23, it can have contradictory effects, ranging 
from  enhancing  immune  responses  to  inducing  suppressive  or  toloregenic  effects22, 
depending  on  the  dose  and  context  in  which  it  is  administered.    In  the  setting  of 
autoimmune diseases, there have also been conflicting observations regarding the role 
of GM-CSF.  A previous study has shown that GM-CSF depletion ameliorates disease in a 
mouse  model  of  rheumatoid  arthritis  and  in  experimental  autoimmune 
encephalomyelitis (EAE)24, suggesting a pathogenic role for GM-CSF in those settings.  
However, a number of other reports have demonstrated that administration of GM-CSF 
can have tolerizing effects and delay disease in mouse models of type 1 diabetes25,26 or 
experimental  autoimmune  myasthenia  gravis  (EAMG)27.    In  particular,  these  studies 
observed that GM-CSF treated DCs led to an increase in FoxP3+ Tregs in vitro28 and in 
vivo25.  A role of GM-CSF in diabetes can also be seen from the fact that aged C57Bl/6 
mice,  which  are  not  normally  prone  to  diabetes,  exhibit  peri-insulitis  when  they  are 
deficient in GM-CSF, and they develop diabetes when they are doubly deficient in GM-
CSF and IL-329. 
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Achieving  substantial  DC  recruitment  likely  requires  physiologically  relevant 
concentrations  of  GM-CSF  to  be  released  in  a  sustained  manner.    Controlling  the 
release of GM-CSF would also limit the amount of GM-CSF reaching systemic circulation.  
This  may  be  important  considering  the  varying  effects  that  GM-CSF  can  have 
depending on the context in which it acts on immune cells.  Alginate can interact with 
heparin-binding  proteins,  such  as  VEGF11,30,  which  are  then  released  in  a  sustained 
manner.  Although GM-CSF does contain a heparin-binding domain, binding to heparin 
only occurs at acidic pH31,32.  Since GM-CSF has an isoelectic point around 4-5, it will be 
negatively  charged  at  neutral  pH  and  will  not  bind  to  heparin,  which  has  a  high 
negative charge density.  Similarly, GM-CSF is not expected to interact with alginate 
polymer  chains,  which  also  bear  a  negative  charge,  under  normal  physiological 
conditions (pH 7.2-7.4).  Based on its small size and its lack of ionic interactions with 
alginate at neutral pH, GM-CSF is expected to diffuse rapidly through alginate gels.  A 
number of different nano- and micro- particle carriers have been developed in the field 
of drug delivery and can be used to control the release of proteins.  Depending on the 
method by which the proteins are incorporated, these different types of particles will 
allow release by different mechanisms.  PLG microspheres formed by a simple water-in-
oil-in-water (w/o/w) emulsion technique can be used to encapsulate proteins, which 
are incorporated into the first water phase4.  Depending on the molecular weight and 
composition  of  the  PLG  polymer,  the  protein  will  be  released  at  a  defined  rate  by 
diffusion through water-filled channels and, at later timepoints, by degradation of the 
polymer.    Mesoporous  silica  (MPS)  particles,  on  the  other  hand,  are  synthesized  to 
contain highly structured pores that can be subsequently loaded with protein33.  The 
diffusion of the protein can be restricted and controlled by using particles in which the 28 
 
pores are only slightly larger than the size of the protein.  Gold nanoparticles (AuNPs) 
form covalent bonds to thiol groups on the surface of proteins, and thus the release of 
the immobilized protein is dependent on the spontaneous dissociation of the gold-thiol 
bonds34.  PLG and MPS, although biocompatible, result in some inflammatory responses 
in  vivo.    This  is  partly  due  to  non-specific  protein  adsorption  and  unfolding,  which 
exposes cryptic epitopes and can initiate inflammatory responses35,36.  Gold has a long 
track record of safety as a dental filling material, and more recent studies have shown 
that gold nanoparticles are  non-cytotoxic and  non-immunogenic to macrophages37 
and  DCs38  in  vitro.  In  addition,  gold  has  been  used  clinically  in  the  treatment 
rheumatoid arthritis, an autoimmune disease39. 
 
The sub-hypothesis for this chapter is that macroporous alginate hydrogels delivering 
GM-CSF can constitute a platform to effectively recruit DCs for downstream immune 
modulation.    Here,  effective  recruitment  of  a  highly  enriched  population  of  DCs  is 
achieved by controlling the release kinetics of GM-CSF from alginate hydrogels, as well 
as the pore structure of the gels. 
 
2.2 Materials and Methods 
 
AuNP synthesis 
AuNPs were synthesized by a citrate-reduction method40.  Briefly, a 250mL erlen-meyer 
flask containing a stir bar were cleaned by first rinsing briefly in aqua regia (1 part nitric 
acid : 3 parts hydrochloric acid) and subsequently rinsing thoroughly in MilliQ-filtered 
(Millipore) H2O.  100mL of 0.01% w/v gold chloride (III) chloride hydrate (Sigma Aldrich # 29 
 
254169) were added to the flask and brought to a boil on a heating and stirring plate 
set to 400°C and 500rpm.  3mL of a 1% w/v sodium citrate tribasic dihydrate (Sigma 
Aldrich # 4641) solution were rapidly added by dispensing forcefully through an 18G 
needle attached to a 10mL syringe.  The solution was removed from the stirring/heating 
plate once its color changed to red. 
The  size  of  the  synthesized  AuNPs  was  determined  by  DLS  on  a  Malvern  Zen  3600 
Zetasizer, and their concentration was determined by measuring absorbance at 518-
519nm on a UV spectrophotometer. 
 
AuNP conjugation 
The amount of GM-CSF to be conjugated to AuNPs was determined by calculating the 
theoretical packing of GM-CSF molecules on the surface of the AuNPs (Appendix A).  
150% of the theoretical amount required to obtain 100% coverage was used to ensure 
complete  coverage  of  AuNPs.    A  sterile-filtered  45ug/ml  AuNP  solution  was 
concentrated 157.5 x by centrifuging at 20,000g for 20min and removing supernatant.  
After resuspending particles by pipetting and sonicating in a water bath sonicator for 
10min, concentrated AuNPs were mixed with a 1mg/mL stock of GM-CSF in dH2O and 
incubated at 37°C for 1 hour to allow formation of the gold-sulfur bonds. 
 
PLG microsphere fabrication 
PLG microspheres were fabricated by a standard double emulsion technique4.  Briefly, 
a 100uL solution of GM-CSF in water was added to 1mL of a 5% solution of PLG (85:15, 
120 kD copolymer of D, L-lactide and glycolide, Alkermes) in ethyl acetate in a silanized 
glass test tube.  The solution was sonicated at 60% at a continuous setting for 10sec 30 
 
using  a  Vibracell  probe  sonicator  (Sonics  &  Materials).    1mL  of  1%  PVA  /  7%  Ethyl 
Acetate in H2O was immediately added and the mixture was vortexed for 10sec.  The 
emulsion was added to 200mL of 0.3% PVA / 7% ethyl acetate in H2O and stirred for 3h.  
Microspheres were collected and washed in H2O. 
 
Mesoporous silica particle loading 
3ug of GM-CSF, containing a small amount of 125I-labeled GM-CSF as a radioactive 
tracer, were added to 2mg of mesoporous silica microparticles in 16uL of dH2O.  The 
particles were incubated with GM-CSF for 1h at 37°C before being flash frozen and 
lyophilized. 
 
In vitro GM-CSF release 
3ug per sample of GM-CSF were used for release studies, unless specified otherwise.  
Particles or gels loaded with GM-CSF were incubated at 37°C in HBSS containining 1% 
BSA (Roche) to block non-specific protein adsorption and 1% penicillin/streptomycin.  
Whenever possible, low protein disposables were used, also to minimize non-specific 
protein adsorption.  At each timepoint, the release buffer was collected and replaced 
with 1mL of fresh buffer.  The amount of GM-CSF released was determined either by 
ELISA or by quantifying a 125I-labeled GM-CSF tracer using a gamma counter. 
 
In vitro GM-CSF bioactivity assay 
Cells were isolated from the bone marrow of C57BL/6J mice, resuspended in RPMI-1640 
media (supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 50uM 
β-mercaptoethanol),  and  4  x  104  cells/well  were  seeded  in  96  black  tissue  culture 31 
 
treated well plates.  A standard curve was prepared by performing 4-fold serial dilutions 
of a 40ng/mL high standard.  100 µl of sample or standard were added, in triplicate, to 
each  well.    Cells  were  incubate  at  37°C  for  5  days,  at  which  point  10%  v/v  of 
AlamarBlue reagent (Life Technologies) was added to each well.  After a 4h incubation 
at 37°C, plates were read on a BioTek plate reader to measure the absorbance at 
490nm.    The  standard  curve  was  used  to  determine  the  level  of  bioactivity  of  the 
experimental  samples  in  “ug  equivalent”.    “Percent  bioactivity”  was  calculated  by 
normalizing  the  “ug  equivalent”  activity  measured  in  the  bioactivity  assay  to  the 
amount of GM-CSF, in ug, detected by ELISA for the same samples.   
 
Alginate modification 
Alginate oxidation and reduction reactions were performed as described previously15,18. 
 
Alginate porogen fabrication 
Pore-forming  gels  were  fabricated  using  medical  grade  alginate.    Porogens  were 
formed by dispensing an alginate solution through a glass nebulizer, applying a coaxial 
flow  of  N2  gas  to  break  up  the  surface  tension,  and  collecting  the  beads  in  a 
crosslinking solution of 100mM CaCl2 and 100mM HEPES.  Beads were washed 3 times by 
resuspending them in an excess of HBSS (Sigma Aldrich) and pelleting them at 1,800g. 
 
Alginate hydrogel fabrication 
A solution of 3% unmodified alginate was first mixed with a solution of GM-CSF or GM-
CSF-loaded  particles  in  DMEM  without  L-cystine  (Sigma  Aldrich).    This  mixture,  which 
constituted the bulk phase of the gels, was then mixed with pre-formed porogen beads.  32 
 
Finally, the bulk gel was crosslinked by mixing with a slurry of CaSO4 dihydrate (8.4g in 
40mL H2O).  The volume of CaSO4 crosslinking solution used was 4% v/v relative to the 
bulk alginate.  All mixing steps were performed using 1mL luer-lock syringes joined with 
luer-lock connectors. 
For in vitro studies, the gels were immediately cast between two silanized glass plates 
separated by 2mm spacers.  After allowing the gels to crosslink for 20 min, gel disks were 
punched out using a sterile 8mm biopsy punch to form ~100uL gels. 
For in vivo studies, an 18G needle was attached to the syringe and gels were injected 
subcutaneously  immediately  after  crosslinking  the  bulk  phase  of  the  gel  (within 
approximately 30-60sec).  The gels stayed in place and continued to crosslink fully after 
injection. 
 
Gel degradation assay 
100μL  alginate  gels  were  incubated  in  release  buffer  at  37°C.    At  the  indicated 
timepoints, gels were flash frozen and lyophilized to determine their dry mass. 
 
Confocal microscopy 
Images  were  taken  using  an  upright  Zeiss  LSM  710  confocal  microscope,  processed 
using ZEN software (Zeiss), and analyzed using ImageJ software (NIH). 
 
Gel wicking assay 
100uL  gels  were  incubated  in  1mL  of  media  at  37°C  to  allow  degradation  of  the 
porogens.  Water wicking was performed by touching an absorbent Kimwipe (Kimberly-
Clark)  to  one  side  of  the  gel,  allowing  the  water  in  the  pores  to  be  drawn  out  by 33 
 
capillary  action.    To  measure  the  wicking  volume,  gels  were  gently  placed  on  a 
disposable tray and weighed on a microbalance before and after wicking. 
 
In vivo cell recruitment studies 
In vivo studies were done in C57BL/6J female mice between 6-12 weeks of age.  Gels 
were injected subcutaneously into one flank.  At various timepoints, gels were removed 
and dissociated in 40mM EDTA on ice for 10min, with periodic vortexing.  For the analysis 
of lymph nodes, the subcutaneous draining LNs, located on the same side as the gel, as 
well as the contralateral irrelevant LNs, were also isolated and mechanically disrupted 
to release the cells.  For both gels and LNs, cells were filtered through 40um cell strainers, 
and  live  cells  were  counted  using  a  Countess  automated  cell  counter  (Life 
Technologies). 
 
Flow cytometry 
Cells were blocked and stained with antibodies from BD Biosciences, eBioscience, and 
BioLegend  (Appendix  B).    7-AAD  (BioLegend)  or  Fixable  Live/Dead  dyes  (Life 
technologies) were used for live and dead cell discrimination.  All  antibody staining 
steps were performed in flow cytometry staining buffer consisting of PBS with 0.5% BSA 
and 2mM EDTA.  Data were collected on either BD LSRII or LSRFortessa flow cytometers 
and analyzed using FlowJo software (TreeStar). 
 
Immunofluorescent staining of frozen sections 
Gels were fixed in fresh, ice-cold 4% PFA in PBS at 4°C for 1h, then rinsed in PBS at 4°C for 
2-3h.  Sucrose infiltration was performed by incubating the gels in 30% w/v sucrose in 34 
 
PBS at 4°C overnight.  Before embedding, gels were incubated in a 1:1 mixture of 30% 
w/v sucrose and OCT (Tissue-Tek) for 1h.  Gels were embedded in OCT in disposable 
molds and stored at -80°C until sectioning on a Leica cryostat.  10um sections were cut 
and  collected  on  Superfrost  Plus  glass  slides  (VWR).  For  staining,  sections  were  first 
hydrated in PBS for 5min and permeabilized in 0.5% Triton X-100 in PBS for 5min.  All 
subsequent washes were performed using a staining buffer consisting of 0.1% Triton X-
100  in  PBS.    Slides  were  blocked  for  30min  at  room  temperature  in  blocking  buffer 
(staining  buffer  +  10%  serum  from  the  same  species  as  the  secondary  antibodies).  
Primary antibodies were applied to slides in 150uL of blocking buffer and incubated at 
4°C overnight, after which the  slides were washed  for 3-4  hours at 4°C.  Secondary 
antibodies were applied to slides in 300uL of blocking buffer and incubated at room 
temperature for 1h, then washed for 1h.  Nuclei were counterstained using a 1:1000 
dilution of Hoechst 33342 (Life Technologies). 
 
Statistical analysis 
When comparing two groups, a two-tailed Student’s t-test was used.  When comparing 
multiple groups, a one-way or two-way analysis of variance (ANOVA) was performed 
with  corrections  for  multiple  comparisons.    When  paired  biological  samples  were 
compared,  the  parameters  of  the  statistical  tests  were  adjusted  accordingly.    All 
statistical analyses were performed using Prism 6 (GraphPad).   
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2.3 Results 
 
GM-CSF release kinetics were modulated using nano- and micro- particle carriers 
 
As a first step towards achieving effective DC recruitment to alginate hydrogels, GM-
CSF release kinetics were engineered to be sustained over several days.  When GM-CSF 
was  incorporated  directly  into  a  2%  w/v  alginate  hydrogel,  over  90%  of  the 
encapsulated protein was released within the first 12 h (Fig. 2.1 A).  To achieve a more 
sustained  delivery  of  GM-CSF,  three  different  nano-  or  micro-  particle  carriers  were 
tested.    GM-CSF  was  covalently  coupled  to  AuNPs,  encapsulated  within  PLG 
microspheres, or incorporated into porous MPS microparticles, following which release 
of  GM-CSF  at  37°C  was  evaluated  over  time  (Fig.  2.1  B).    50%  of  the  GM-CSF  was 
released from AuNPs in first day, whereas 65% and 75% of the GM-CSF were released 
from the PLG microspheres and MPS, respectively, in the same time period.  After 4 
weeks,  the  PLG  microspheres  had  the  highest  fraction  of  unreleased  GM-CSF  still 
associated with the particles.  The final percentages of GM-CSF released at the end of 
the timecourse were 79% for PLG, 90% for MPS, and 98% for AuNPs.  Together, these 
results demonstrated that GM-CSF release from AuNPs, which requires dissociation of a 
covalent bond, was the most gradual and sustained over the first few days, as well as 
the most complete over the course of four weeks.  AuNPs were selected for GM-CSF 
delivery in subsequent work for these reasons, as well as the fact that gold is expected 
to be the least inflammatory material among the three that were tested. 
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Figure 2.1.  Micro- or nano- particle carriers controlled GM-CSF release kinetics.  (A) 
GM-CSF release after direct incorporation in nanoporous alginate gels.  3ug of GM-CSF 
were encapsulated in ionically crosslinked alginate hydrogels, which were incubated at 
37°C in release buffer.  GM-CSF release into the supernatant was measured by ELISA. (n 
= 5; mean ± s.d. shown).  (B) GM-CSF release from micro- or nano- particle carriers.  For 
AuNP and PLG, GM-CSF release was quantified by ELISA; for MPS, 125I-labeled GM-CSF 
was used as a radioactive tracer.  (n = 5; mean ± s.d. shown). 
 
Incorporation of GM-CSF conjugated AuNPs in alginate hydrogels resulted in sustained 
GM-CSF release 
 
AuNPs coated with GM-CSF were incorporated into alginate gels to form a controlled 
delivery system that could also serve as a physical scaffold for cell infiltration.  First, an in 
vitro assay was developed using primary bone marrow cells to test the bioactivity of 
GM-CSF after conjugation to and release from AuNPs.  Across all timepoints, samples of 
GM-CSF released from AuNPs exhibited greater than 100% bioactivity (Fig. 2.2).  At 3h, 
6h, and 12h, the bioactivity levels  were 166%, 155%, and 141%, respectively.   At the 
subsequent timepoints, from day 1 and on, the bioactivity remained constant, around 
125%. 37 
 
 
Figure  2.2.    GM-CSF  remained  bioactive  following  release  from  AuNPs.  GM-CSF-
conjugated AuNPs were incubated at 37°C in release buffer and supernatants were 
removed at each timepoint.  Release samples were used in an in vitro bioactivity assay 
and compared to a standard curve to determine their level of bioactivity.  The same 
samples were quantified by ELISA to determine the amount of GM-CSF in ug.  (n = 5; 
mean ± s.e.m. shown). 
 
It was found that GM-CSF dissociated rapidly from AuNPs in the presence of cystine, 
exhibiting 77% release into the supernatant in only 3 hours, and almost 98% release by 
24 hours (Fig. 2.3 A).  In contrast, the retention of GM-CSF on AuNPs was significantly 
higher in cystine-free media (Fig. 2.3 B).  After 18 hours, the fraction of GM-CSF that 
remained conjugated to the AuNPs was 91% in HBSS, and 78% in cystine-free DMEM.  For 
both of these conditions, there was still a statistically significant reduction in the amount 
of GM-CSF remaining on the AuNPs compared to the 0h control, in which ~96% of the 
GM-CSF was bound, indicating that the GM-CSF was still being released.  In light of 
these findings, GM-CSF-conjugated AuNPs were incorporated into alginate hydrogels, 
and the profiles of GM-CSF release were compared between gels formulated with and 
without cystine (Fig. 2.3 C).  When GM-CSF release from cystine-free gels was measured, 
the resulting GM-CSF release profile was similar to the release from AuNPs alone (Fig 2.1 38 
 
B).  On the other hand, when gels were formulated using standard media containing 
cystine,  the  release  of  GM-CSF  was  almost  identical  to  the  release  of  free  GM-CSF 
incorporated  directly  into  gels  without  AuNPs  (Fig  2.1  A).    Together,  these  results 
demonstrated that AuNPs could be used to deliver bioactive GM-CSF from alginate 
hydrogels, and that the release rate would be gradual and sustained, provided that 
the gels were formulated without cystine. 
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Figure  2.3.    GM-CSF  release  was  gradual  and  sustained  when  GM-CSF  conjugated 
AuNPs were incorporated into alginate hydrogels formulated without cystine.  (A-B) GM-
CSF release from AuNPs in cystine containing media, such as standard DMEM (A), or in 
cystine-free  media  (B).    AuNPs  were  conjugated  to  GM-CSF,  then  mixed  with  the 
indicated media and incubated at 37°C for the indicated time.  The amounts of GM-
CSF released into the media or still associated with the particles were quantified  by 
ELISA.    (n  =  3;  mean  ±  s.d.  shown;  ***  p  <  0.001;  ****  p  <  0.0001).  (C)  AuNPs  were 
conjugated to 3μg of GM-CSF and incorporated into 100μL alginate gels formulated 
either with or without cystine.  Gels were incubated at 37°C in 1mL of release buffer, 
and supernatants were removed at each timepoint to quantify the amount of released 
GM-CSF by ELISA.  (n = 5; mean ± s.d. shown). 
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Pore-forming gel properties were modulated to allow cell infiltration  
 
Pore-forming alginate hydrogels, which are formed by incorporating rapidly degrading 
porogen beads into a bulk gel (Fig. 2.4), were characterized and optimized for in vivo 
recruitment of DCs in response to GM-CSF.  The effects of varying different fabrication 
parameters  on  porogen  degradation  and  size  were  examined.    The  degradation 
kinetics for different alginate formulations at 37°C were determined (Fig. 2.5 A).  2% w/v 
alginate  hydrogels  made  from  7.5%  oxidized/reduced  alginate  degraded  almost 
completely in only 3 days.  In contrast, unmodified alginate gels showed a small initial 
reduction in dry mass, which was likely due to the diffusion of sulfate ions and unbound 
calcium  ions  following  crosslinking,  but  the  dry  mass  then  plateaued  and  remained 
stable  over  time,  indicating  that  the  gels  did  not  degrade.    Binary  mixtures  of  7.5% 
oxidized/reduced  alginate  with  a  small  amount  of  unmodified  alginate  exhibited 
intermediate  degradation  profiles.    A  combination  of  2%  w/v  oxidized/reduced 
alginate  together  with  0.25%  w/v  unmodified  alginate  was  selected  for  subsequent 
work since it displayed sufficient mechanical stability to withstand the porogen bead 
fabrication process, yet still degraded rapidly, exhibiting 70% degradation in 5 days.  
Varying the composition of the polymer affected not only the degradation rate, but 
also  the  size  of  the  porogen  beads,  since  oxidized/reduced  alginate  had  a  lower 
molecular  weight  distribution  than  unmodified  alginate  as  a  result  of  the  oxidation 
process, and thus a lower viscosity.  Increasing the amount of unmodified alginate led 
to larger diameter porogen beads, while  increasing the  coaxial airflow rate  yielded 
smaller diameter porogens (Fig. 2.5 B).  These porogens formed a separate phase within 
the gel, even after mixing and crosslinking the bulk gel (Fig. 2.5 C).  After incubation at 41 
 
37°C in vitro, the interconnected porosity of pore-forming gels was significantly higher 
than  that  of  nanoporous  gels,  indicating  that  the  porogens  degraded  and  formed 
voids within the bulk gel (Fig. 2.5 D). 
 
A              B 
     
Figure 2.4.  Pore-forming hydrogels were created by incorporating rapidly degrading 
porogen beads into a bulk gel.  (A) Formation of a network of voids, or pores, following 
the degradation of porogen beads within a bulk gel.  (B) Setup for porogen fabrication.  
– Diagrams adapted from Huebsch et al. 
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Figure 2.5 (continued).  Degradable alginate porogens formed a separate phase within 
a bulk alginate hydrogel and created a macroporous structure as they degraded.  (A) 
In vitro degradation kinetics of alginate gels consisting of 2% w/v unmodified (unmod) 
alginate, 2% w/v oxidized then reduced (oxi/red) alginate, or binary mixtures of oxi/red 
and unmod alginate.  (n = 3; mean ± s.d. shown).  (B) Size distributions of porogens 
fabricated  with  different  coaxial  airflow  rates  (SLPM  of  N2  gas)  and  percentages  of 
unmod alginate (all conditions contained 2% w/v oxi/red alginate).  Labeled porogens 
were imaged by confocal microscopy.  Maximum intensity projections were obtained 
from  confocal  Z-stacks  and  thresholded  to  analyze  particle  size  (maximum  Feret’s 
diameter in um).  (C)  Confocal Z-slice of a pore-forming gel containing FITC-labeled 
porogen beads (green) within a bulk gel.  White dotted line demarcates gel border.  (B) 
Interconnected  porosity  of  nanoporous  and  macroporous  pore-forming  gels,  as 
measured by a wicking assay.  (n = 4; mean ± s.d. shown; * p < 0.05).   
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Pore-forming gels delivering GM-CSF in vivo mediated substantial cell recruitment 
 
To examine cell recruitment in vivo, pore-forming gels delivering GM-CSF conjugated to 
AuNPs were injected subcutaneously into the flanks of mice.  The protein-coated AuNPs 
were incorporated into the bulk, non-degrading phase of pore forming gels.  To test 
whether  the  AuNPs  exerted  any  effects  independently  of  GM-CSF,  AuNPs  were 
conjugated to a control protein, consisting of Fab fragments from mouse IgG.  Mouse 
Fab fragments are not expected to elicit any biological activity, since they are native 
proteins,  and, unlike  Fc fragments, they will not be bound by specialized  receptors.  
Since Fab fragments are larger than GM-CSF (diameters were approximated to be 5nm 
and 3.4nm, respectively), the amount of protein was reduced to maintain the same 
surface coverage of the AuNPs while still delivering the same number of AuNPs.  Gels 
that did not contain any GM-CSF, i.e. blank gels and gels containing control AuNPs, did 
not  mediate  substantial  cell  recruitment  (Fig.  2.6).    Gels  delivering  soluble  GM-CSF 
showed an accumulation of ~1.6 x 106 cells at day 3, and the number of cells in the gels 
remained higher than in the conditions without GM-CSF for the rest of the timecourse.  
Strikingly, when GM-CSF was conjugated to AuNPs and delivered in gels, over 5 million 
cells were recruited into the gels at the peak of cell infiltration (Fig. 2.6 A).  While the 
number of cells in the gels decreased after day 3, there were still close to 3 x 106 cells in 
the gels at day 5, and ~106 cells were maintained in the gels up until 14 days after 
injection.  AUCs were calculated to estimate the total number of cells residing in the 
gels over the course of two weeks (Fig. 2.6 B).  Gels delivering GM-CSF conjugated to 
AuNPs had an AUC of ~24 x 106, which was significantly higher than all of the other 
conditions.  The AUC for gels delivering soluble GM-CSF was ~12 x 106, which was 2-fold 44 
 
lower than for the gels delivering GM-CSF conjugated to AuNPs.  Although the gels with 
soluble GM-CSF exhibited more cell infiltration than blank gels or gels with control AuNPs, 
the differences in AUCs were not statistically significant.  These results showed that the 
delivery  of  GM-CSF  conjugated  to  AuNPs  in  pore-forming  alginate  gels  was  highly 
effective at recruiting a large number of cells into the gels over a period of two weeks, 
with the peak of cell infiltration occurring at day 3.  The observation that the number of 
cells recruited was significantly higher for GM-CSF conjugated to AuNPs compared to 
soluble GM-CSF demonstrated that control over GM-CSF release kinetics was indeed 
important for optimal cell recruitment. 
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Figure  2.6.  Pore-forming  gels  delivering  GM-CSF  conjugated  to  AuNPs  mediated 
substantial cell recruitment in vivo.  Gels were injected subcutaneously into the flanks of 
C57BL/6J mice.  At specified timepoints, gels were dissociated to retrieve and quantify 
infiltrating cells.  (A) Number of live cells in gels over time.  (n = 3 - 9 per condition per 
timepoint; mean ± s.d. shown; * p < 0.05 compared to Blank and AuNP; **** p < 0.0001 
compared to all other conditions; AuNP + GM-CSF condition was compared to all other 
conditions  at  each  timepoint.)    (B)  Areas  under  curves  corresponding  to  the  cell 
recruitment data shown in (A).  (* p < 0.05; *** p < 0.001; all conditions were compared 
to each other.) 
 
To  determine  whether  the  structural  properties  of  the  pore-forming  gels  had  a 
significant impact on cell recruitment, the volume fraction of the porogens, as well as 
the  total  gel  volume,  were  altered.    A  porogen  volume  fraction  of  50%  led  to 
significantly more cell infiltration than a 25% porogen volume, which indicated that the 46 
 
incorporation of degradable porogens facilitated cell infiltration into the gels (Fig. 2.7).  
Unexpectedly, 3 days after injection of the gels, at the peak of cell infiltration, a 50% 
porogen fraction allowed significantly more cell infiltration than a higher 75% porogen 
fraction.  When the porogen volume fraction was maintained at 50%, doubling the total 
volume of the gels from 100uL to 200uL led to significantly higher cell infiltration at days 
5  and  10,  even  though  the  amount  of  GM-CSF  delivered  remained  constant.    The 
increased accumulation in the 200uL gels may have been a  reflection an impaired 
ability of the cells to migrate out of the larger volume gels and be redeployed, rather 
than an enhancement in cell recruitment.  Based on these data, the 100μL gels with a 
50% porogen volume were selected as being optimal for subsequent experiments. 
 
 
Figure 2.7. Modulating the volume and porogen fraction of pore-forming gels controlled 
the  number of  recruited cells.  Gels were  injected subcutaneously into  the  flanks  of 
C57BL/6J mice.  At specified timepoints, gels were dissociated to retrieve and quantify 
infiltrating cells.  (n = 3 - 9 per condition per timepoint; mean ± s.d. shown; * p < 0.05; **** 
p < 0.0001; 100uL 50% porogen condition was compared to all other conditions at each 
timepoint.) 
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Recruited cells were highly enriched in CD11c+ dendritic cells 
 
The cells recruited into this gel system were characterized by analyzing a variety of cell 
surface markers associated with immune cells.  For all the timepoints and conditions 
examined, the vast majority of cells (~80-98%) were CD11b+ (Fig. 2.8 C).  A very high 
percentage of the cells across all timepoints and conditions were also CD11c+ (Fig. 2.8 
D).  At day 3, the gels delivering GM-CSF conjugated to AuNPs contained 68% CD11c+ 
cells,  which  was  significantly  lower  than  the  89%  CD11c+  cells  found  in  the  gels 
delivering soluble GM-CSF.  However, by day 5, the fraction of CD11c+ cells in gels with 
GM-CSF  +  AuNP  increased  to  94%.    Histological  examination  confirmed  that  the 
recruited cells expressed CD11c+, and also demonstrated that the cells were able to 
infiltrate all the way into the center of the gels as early as 3 days after gel injection (Fig. 
2.8 B). 
 
A substantial percentage of the CD11b+ CD11c+ double positive cells in the gels also 
expressed F4/80, a marker of macrophages that is also expressed on some DC subsets 
(Fig. 2.8 E).  The gels delivering GM-CSF conjugated to AuNPs showed a trend towards a 
lower fraction of F4/80+  cells compared  to  the  other conditions, with some  of these 
differences being statistically significant at days 3 and 10.  At day 3, the peak of cell 
infiltration,  around  30%  of  the  cells  expressed  Gr-1,  a  marker  of  monocytes  and 
granulocytes, when GM-CSF conjugated to AuNPs was delivered in the gels (Fig. 2.8 F).  
This was significantly higher than in the other conditions, which only had ~8-20% Gr-1+ 
cells  at  this  same  timpoint.    At  later  timepoints,  this  population  was  reduced  and 
constituted less than 5% of the cells found in gels delivering GM-CSF + AuNP.  Finally, the 48 
 
fraction of cells positive for DX5, an antibody clone that binds to CD49b and labels NK 
cells, as well as some NKT cells and T cells, was examined.  At day 5, the fraction of cells 
positive for DX5 was only 5% in gels delivering GM-CSF + AuNP, which was significantly 
lower than in the conditions that did not contain GM-CSF (Fig. 2.8 G).  However, at day 
14, this relationship was reversed, such that gels delivering GM-CSF + AuNP contained 
significantly more DX5+ cells than in the other conditions, around ~25%.  Overall, the 
data  show  that  pore-forming  gels  delivering  GM-CSF  recruited  cells  that  were 
predominantly CD11b+ CD11c+ (Fig. 2.8 A), with a large fraction of these also being 
F4/80+. 
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Figure  2.8  (continued).  Gels  delivering  GM-CSF  in  vivo  recruited  a  highly  enriched 
population of DCs.  Gels were injected subcutaneously in the flanks of C57BL/6J mice.  
At  specified  timepoints,  gels  were  dissociated  to  retrieve,  quantify,  and  analyze 
infiltrating cells.  (A) Flow cytometry plot of CD11b+ CD11c+ cells isolated from a gel 
delivering GM-CSF + AuNPs after 5 days.  (B) Immunofluorescent staining of a sectioned 
gel delivering GM-CSF + AuNPs 3 days after injection.  10um sections were stained for 
CD11c (red), MHCII (green), and nuclei (blue).  (C-G)  Frequency of cells expressing cell 
surface markers CD11b (C), CD11c (D), F4/80 (E), Gr-1 (F), and DX5 (G).  (n = 3 per 
condition per timepoint; mean ± s.d. shown; * p < 0.05; *** p < 0.001; **** p < 0.0001; GM-
CSF + AuNP condition was compared to all other conditions at each timepoint.) 
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Since  the  percentage  of  CD11b+  CD11c+  DCs  was  so  high  in  the  first  two  weeks, 
conversely, the percentage of other cell types in the gels was low.  At later timepoints, 
i.e. day 17 and 21, the fraction of CD11b+ CD11c+ cells was around 50-60%, and the 
expression of other immune cell markers was examined.  B cells were almost completely 
absent from the gels, constituting <1% of all cells, while the fraction of T cells was ~5-8% 
at days 17 and 21 (Fig. 2.9 A).  Notably, the majority of the T cells were CD4+ helper T 
cells, with less than 10% of the T cells being CD8+ cytotoxic T cells (Fig. 2.9 B).  Of the 
CD4+ T cells, > 55% expressed CD25, the high-affinity IL-2 receptor that is expressed on 
Tregs, as well as transiently on activated T cells (Fig. 2.9 C). 
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Figure 2.9.  A small fraction of CD4+ CD25+ T cells was present in gels delivering AuNP + 
GM-CSF  at  later  timepoints.  Gels  were  injected  subcutaneously  in  the  flanks  of 
C57BL/6J mice.  At specified timepoints, gels were dissociated to retrieve, quantify, and 
analyze infiltrating cells.  (A-C) Quantification of flow cytometry data at days 17 and 21 
after  gel  injection.    (A)  Percentage  of  T  cells,  B  cells,  and  DCs  found  in  gels.    (B) 
Percentage  of  T  cells  that  are  CD4+  helper  T  cells  or  CD8+  cytotoxic  T  cells.    (C) 
Percentage of CD4+ T cells expressing CD25.   (n = 3 per condition per timepoint; mean 
± s.d. shown).   53 
 
The lymph nodes of mice that received gels delivering GM-CSF conjugated to AuNPs 
were  examined  to  determine  whether  any  changes  in  cell  number  or  composition 
could be observed in the draining lymph nodes.  The lymph nodes draining the gels 
contained significantly more cells than the irrelevant lymph nodes on the contralateral 
flank  at  days  5  and  10  (Fig.  2.10  A).    In  addition,  a  statistically  significantly  higher 
percentage of CD11c+ cells was found in the draining lymph nodes compared to the 
irrelevant lymph nodes at days 3 and 5 (Fig 2.10 B). 
 
A              B 
 
Figure 2.10. Administration of gels delivering GM-CSF led to an increase in the number 
and percentage of CD11c+ cells in the draining lymph nodes compared to irrelevant 
lymph nodes.  Gels were injected subcutaneously in one flank of C57BL/6J mice.  At 
specified timepoints, the LNs draining the gel (dLN) and the irrelevant LNs (iLN) on the 
contralateral side were isolated and dissociated to enumerate total cells (A) as well as 
the percentage of CD11c+ cells (B).  (n = 3 - 9 per condition per timepoint; individual 
data points shown with lines connecting paired samples isolated from the same mouse; 
* p < 0.05; ** p < 0.01; *** p < 0.001). 
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2.4 Discussion 
 
The  material  system  developed  here,  which  consisted  of  an  injectable,  non-
inflammatory,  pore-forming  hydrogel,  mediated  an  impressive  local  enrichment  of 
CD11c+  DCs  following  the  release  of  a  DC  recruitment  factor.    Optimal  cell 
accumulation was achieved by controlling both the release kinetics of the recruitment 
factor, GM-CSF, as well as the physical structure of the hydrogel.  Since the hydrogel 
was  engineered  to  be  macroporous,  the  recruited  DCs  were  able  to  infiltrate 
throughout  the  material,  representing  an  opportunity  to  control  their  behavior  by 
exposing them to a defined microenvironment within the hydrogel. 
 
Since GM-CSF does not interact with alginate, several different particle carriers were 
tested for their ability to delay GM-CSF release from alginate hydrogels.  The different 
types  of  particles  were  all  able  to  mediate  sustained  release  of  GM-CSF.    AuNPs 
exhibited the most slow and gradual GM-CSF release over the first few days, but also 
the most complete release at the end of four weeks.  The PLG microparticles retained 
the highest amount of unreleased GM-CSF at the end of four weeks, likely due to the 
fact that release from PLG is first diffusion controlled, then degradation controlled.  For 
PLG  with  an  85:15  lactide:glycolide  ratio,  complete  degradation  is  achieved  by  35 
weeks, but no significant weight loss occurs until after 10 weeks41, so the PLG would not 
have  degraded  substantially  in  the  timeframe  of  this  release  study.    AuNPs  were 
selected for subsequent use in the material system because they exhibited a gradual 
and sustained release of GM-CSF, and also because gold is expected to be inert and 
non-inflammatory in vivo. 55 
 
 
The bioactivity of GM-CSF was tested after its release from AuNPs, and it was found to 
be  greater  than  100%  at  all  timepoints  up  until  4  weeks,  at  which  point  98%  of  the 
measured GM-CSF had been released from the particles.  This demonstrates that the 
formation  and  dissociation  of  gold-thiol  bonds  did  not  lead  to  significant  protein 
unfolding  or  denaturation.    In  fact,  the  samples  showed  >~125%  bioactivity  at  all 
timepoints, with the highest percent bioactivity seen in the first 12 hours (166% at 3h, 155% 
at 6h, and 141% at 12h).  The pore size of nanoporous alginate gels is on the order of 5-
6nm19, so the 13nm diameter AuNPs used here were expected to remain entrapped, 
exhibiting little  to  no  diffusion  out  of  the  gels.    However,  release  of  AuNPs  from  the 
surface  of  the  gel  at  the  earliest  timepoints  could  explain  the  unexpectedly  high 
percent bioactivity that was observed, since multivalent GM-CSF presentation on the 
AuNPs may result in more potent bioactivity. 
 
The presence of cystine was found to accelerate the release of GM-CSF from AuNPs, so 
the gel system was formulated to be free of cystine in order to maintain a more gradual 
release.  Although a very gradual and sustained release of GM-CSF from AuNPs was 
achieved in vitro, it is unclear how closely the measured in vitro release profile matches 
the  actual  in  vivo  release  kinetics.    The  levels  of  thiol-containing  molecules  such  as 
cysteine, cystine, and glutathione were  reported to be on the order of 10-100uM in 
plasma  and  tissues42,43,  which  is  a  similar  order  of  magnitude  to  what  is  found  in 
common media (DMEM and RPMI-1640 contain 200uM of cystine).  Upon injection of 
the gels in vivo, endogenous thiol-containing molecules, as well as other proteins, will 
diffuse into the gel and likely lead to GM-CSF release that is accelerated compared to 56 
 
the  in  vitro  release  performed  in  the  absence  of  cystine.    However,  additional 
complexities of the in vivo environment, i.e. the presence of many other proteins and 
biomolecules,  make  it  difficult  to  predict  the  resulting  in  vivo  release  kinetics.  
Quantifying GM-CSF released from the material directly in vivo is challenging, in large 
part because it is not possible to distinguish the exogenous recombinant murine GM-
CSF delivered in the gels from the endogenous murine GM-CSF secreted by immune 
cells.    It  would  be  possible  to  deliver  GM-CSF  from  another  species,  such  as 
recombinant  human  GM-CSF,  and  quantify  it  independently  from  the  endogenous 
murine  GM-CSF.    However,  GM-CSF  molecules  from  different  species  have  slightly 
different  heparin-binding  characteristics31,  so  this  approach  would  not  be  entirely 
representative either.  Despite the fact that its in vivo release may be more rapid than 
what was measured in vitro, GM-CSF conjugated to AuNPs still has a much more potent 
biological effect in vivo than free GM-CSF.  Indeed, significantly more cell infiltration into 
the gels was observed when GM-CSF was conjugated to AuNPs compared to when it 
was incorporated directly in the alginate.  This effect cannot be attributed to the AuNPs 
themselves, since gels containing AuNPs conjugated to a control protein were similar to 
the blank gels and did not induce substantial cell accumulation.  The strategy of using 
AuNPs as a carrier could potentially be applied to control the release of other non-
heparin-binding proteins from alginate. 
 
The delivery of GM-CSF conjugated to AuNPs in pore-forming alginate gels led to the 
infiltration of up to 5 x 106 cells into the gels, the majority of which were CD11b+ CD11c+ 
DCs.  In contrast, only ~1.5 x 106 cells accumulated in gels delivering free GM-CSF, even 
at the peak of cell infiltration.  In blank gels or gels delivering control AuNPs, barely a 57 
 
few hundred thousand cells were detected, and a portion of those cells may actually 
have been scraped off from surrounding tissue in the process of isolating the gels for 
analysis.  The CD11b+ CD11c+ phenotype of the DCs seen here was consistent with a 
report showing that administration of PEG-modified GM-CSF, which has an extended 
circulation  time  in  vivo,  preferentially  expanded  CD11bhighCD11chigh  but  not 
CD11blowCD11chigh DCs44.  However, it is unclear exactly how GM-CSF delivery led to the 
observed accumulation of cells in the gels, since GM-CSF can exert a wide variety of 
effects on its target cells.  It is likely that multiple mechanisms, such as DC migration, 
pre-DC  differentiation,  and  proliferation,  all  contributed  to  some  extent.    It  was 
interesting to note that, while delivery of GM-CSF conjugated to AuNPs had a striking 
effect on the number of cells that accumulated in the gels, the overall surface marker 
expression of the cells was not significantly altered.  This suggests that GM-CSF induced 
proliferation may be playing an important role in expanding recruited DCs.  In addition, 
immune cells such as monocytes and DCs secrete their own chemokines, including GM-
CSF.  It is possible that endogenous factors produced by cells infiltrating the gels in the 
initial  stages  of  cell  recruitment  amplified  the  effect  of  the  delivered  GM-CSF  and 
contributed to the observed cell accumulation. 
 
Tuning  the  physical  properties  of  the  hydrogel  had  a  significant  impact  on  cell 
recruitment.  In these studies, an  intermediate  porogen volume fraction of 50% was 
optimal for achieving maximal recruitment of DCs.  At a lower porogen volume fraction, 
fewer cells were  able to infiltrate  the gels, supporting the importance  of creating a 
macroporous structure to achieve effective cell recruitment.  However, increasing the 
porogen volume fraction beyond 50% did not further improve cell infiltration, possibly 58 
 
because the bulk gel may collapse as the porogens degrade if the porogen fraction is 
too  high,  resulting  in  sub-optimal  cell  infiltration.    Although  the  incorporation  of  50% 
degradable porogens by volume led to a significant increase in the interconnected 
porosity of the gels, the level of interconnected porosity achieved (~13%) was not as 
high as what has been seen in other macroporous gel systems17.  However, cells are still 
able to infiltrate into the center of the gels after only 3 days in vivo, so even a modest 
level of interconnected porosity appears to be sufficient for effective cell infiltration in 
this particular system.  In addition, the effective interconnected porosity may actually 
be greater in vivo, since the gels are subject to mechanical stresses exerted by tissues 
and infiltrating cells, which may lead to the formation of local fractures within the gels 
and the creation of new connections between pores. 
 
Strikingly, this material system recruited not only a large number, but also a very high 
purity of DCs.  At D3, more that 90% of the cells in the gels were double positive for 
CD11b, a broadly expressed marker for leukocytes, and CD11c, a characteristic marker 
of  conventional  DCs.    This  percentage  is  higher  than  what  was  achieved  in  other 
material systems using comparable doses of GM-CSF4 (other unpublished data from the 
Mooney lab).  One possible explanation for this pronounced enrichment of DCs may be 
that the intentional absence of adhesion ligands on the alginate polymer forming the 
gels  favors  infiltration  by  immune  cells.    Most  other  mammalian  cell  types  require 
adhesion ligands for survival and migration.  Leukocytes, on the other hand, can traffic 
in an integrin-independent manner by amoeboid migration45–47.  As a result, the gels 
may be selectively restricting infiltration by fibroblasts and other cells from neighboring 
tissues, such that the gels are infiltrated almost exclusively by DCs.  It would be of great 59 
 
interest and utility to extend this approach to recruit other immune cell types, such as T 
and B cells, using different chemokines or recruitment factors. 
 
A characterization of several other immune cell surface markers in addition to CD11b 
and  CD11c  revealed  that  many  of  the  CD11b+  CD11c+  double  positive  cells  also 
expressed F4/80, which is often cited as a macrophage marker, but is also expressed on 
certain subsets of DCs, including BMDCs48, Langerhans cells, some skin-draining DCs49, 
and some less mature splenic DCs50.  Some of the CD11b+ cells also expressed Gr-1, a 
marker of monocytes and granulocytes, particularly at early timepoints.  The Gr-1+ cells 
isolated from these gels had a forward scatter (FSC) / side scatter (SSC) profile when 
analyzed by flow cytometry that appeared consistent with monocytes.  It is interesting 
to note that day 3, the timepoint at which the fraction of Gr-1+ cells was the highest in 
the gels delivering GM-CSF conjugated to AuNPs, was also the same day at which the 
fraction of CD11c+ cells was the lowest.  Observing the trends in the percentage of 
CD11c+  and  Gr-1+  cells  for  the  different  conditions  at  each  timepoint  suggests  that 
these markers may vary in an inversely proportional manner.  Indeed, the expression of 
these two markers on the cells was segregated, with few cells coexpressing CD11c and 
Gr-1.  It could be speculated that these Gr-1+ cells represent a population of monocytes 
or pre-DCs that migrate and differentiate into CD11c+ DCs upon exposure to GM-CSF.  
Finally, a small fraction of the cells were found to be positive for DX5, an antibody clone 
that binds to CD49b and is typically used as a marker of NK cells.  It is unclear whether 
all of the DX5+ cells here are bona fide NK cells, since a number of them coexpress 
CD11c  and  have  higher  FSC  and  SSC  than  would  be  expected  for  NK  cells,  which 
usually have the low FSC/SSC profile that is typical of lymphocytes.  These cells may be 60 
 
an intermediate cell type, perhaps similar to the CD11c+ DX5+ bitypic NK/DC regulatory 
cells  that  were  described  as  being  protective  in  a  model  of  virally  induced  type  1 
diabetes51.    An  additional  barrier  to  distinguishing  NK  cells  from  NKT  cells  or  T  cells 
without a more extensive analysis is that these lymphocytes all have a similar FSC / SSC 
profile, and that some subsets of T cells, such as Tr1 cells, express CD49b52. 
 
Preliminary evidence suggests that these DCs were redeployed into the local draining 
lymph  nodes,  since  the  number  of  cells  in  the  LNs  draining  the  gels,  as  well  as  the 
percentage  of  CD11c+  cells,  were  significantly  increased  compared  to  the 
contralateral irrelevant LNs.  DC homing to the LNs is critical for generating downstream 
immune  responses,  since  LNs  are  the  meeting  points  where  DCs  interact  with  large 
numbers of T cells, greatly increasing their chances of encountering antigen-specific T 
cells.    It  must  be  noted  that  the  increase  in  the  total  cell  number  was  not  fully 
accounted for by the increase in the percentage of CD11c+ DCs.  Since no exogenous 
antigens were provided here, the increase in T and B cells was not expected to be a 
result of proliferation.  It is speculated that an increase in the number of DCs trafficking 
to  the  LNs  may  result  in  increased  LN  homing  of  the  other  cell  types,  rather  than 
proliferation. 
 
The material system introduced here represents a platform that can be used to recruit a 
highly enriched population of CD11c+ DCs in a non-inflammatory environment, possibly 
enabling the development of a materials-based tolerogenic vaccine. 
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Chapter 3. DCs recruited to alginate gels releasing GM-CSF in vivo are immature 
and have the capacity to induce antigen-specific T cell responses 
 
3.1 Introduction 
 
The  immune  system  has  an  exquisite  capacity  to  mount  highly  antigen-specific 
responses, both for the purposes of generating immunity against pathogens, as well as 
for maintaining tolerance to self.  Vaccination, which has been used successfully for 
over ~200 years now, since the introduction of the smallpox vaccine by Edward Jenner1, 
is  highly  antigen  specific.    Through  the  administration  of  an  attenuated  pathogen 
accompanied by an adjuvant, vaccination evokes precisely targeted immunity.  On 
the other hand, still today in 2014, the therapies in the clinic for treating autoimmune 
diseases  involve  coarser  manipulations  of  the  immune  system  that  are  not  antigen 
specific.    The  use  biomaterials  may  greatly  enhance  our  ability  to  induce  antigen-
specific tolerogenic responses by controlling the presentation of defined self-antigens 
and  by  co-delivering  cues  that  program  immune  cells  for  tolerance.    This  chapter 
addresses specific Aim 2 of this thesis by examining the ability of the material system 
described in the previous chapter to induce antigen-specific T cell responses. 
 
The development of antigen-specific tolerogenic therapies would be transformative in 
the  areas  of  autoimmunity,  as  well  as  transplantation  tolerance.    Although  broad 
immunosuppression  can  alleviate  autoimmune  disease,  it  would  be  preferable  to 
specifically  block  self-reactive  immunity,  while  maintaining  the  full  capacity  of  the 
immune system to clear foreign antigens and pathogens.  While individuals predisposed 67 
 
to autoimmunity may have some underlying defects in components of their immune 
systems, the fact that not all such individuals progress to the disease state suggests that 
it could be possible to restore tolerance, even in the context of genetic predispositions.  
A number of clinical trials have attempted to treat human autoimmune diseases in an 
antigen-specific manner by taking advantage of the known tolerogenic properties of 
mucosal  DCs.    These  studies,  which  involved  delivering  disease-associated  proteins 
either orally or nasally, have essentially all failed, despite the fact that these treatment 
strategies  were  effective  in  many  pre-clinical  models2.    One  possible  reason  for  this 
discrepancy  is  that  in  pre-clinical  models,  these  antigen-specific  therapies  have 
primarily been used prophylactically, prior to the onset of disease, while most clinical 
studies  have  been  done  in  patients  with  recent-onset  disease,  largely  for  ethical 
reasons2.  Research in this area is still ongoing, and a large parameter space still remains 
to  be  explored  for  translating  these  treatments  into  humans,  such  as  antigen  dose, 
formulation, and frequency of administration, as well as the stage of disease at which 
the therapy should be administered.  Recently, though, significant concerns have been 
raised regarding the safety of administering autoimmune disease-associated antigens 
through systemic routes, which include intravenous, oral, and nasal administration.  In 
animal models of multiple sclerosis (MS), delivery of soluble disease-associated peptides 
was  shown  to  induce  fatal  anaphylaxis  in  some  mouse  models,  as  well  as  lead  to 
disease exacerbation in a non-human primate study3.  The ability to deliver peptides in 
a  localized  and  controlled  manner  could  be  key  to  developing successful  antigen-
specific tolerogenic therapies. 
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DCs are an ideal cell type to target for eliciting antigen-specific immune tolerance, 
since  they  integrate  multiple  signals  from  their  environment,  present  peptides  to 
antigen-specific T cells, and direct T cell differentiation and activation.  DCs are critical 
for maintaining self-tolerance in steady state conditions, as demonstrated by the fact 
that depletion of CD11c+ DCs breaks this tolerance, leading to spontaneous and fatal 
autoimmunity4.  In another study, depletion of CD11c+ DCs led to greater severity in 
EAE5,  whereas,  in  contrast,  inducing  DCs  to  present  self-antigens  led  to  disease 
prevention by a PD-1 dependent mechanism.  In the steady state, DCs are immature, 
expressing  low  levels  of  costimulatory  molecules,  such  as  CD80,  CD86,  and  CD406,7.  
Immature DCs have a high capacity for capturing and processing antigen, as well as 
high  levels  of  intracellular  MHCII,  but  low  levels  of  surface  MHCII.    When  DCs  are 
exposed to DAMPs or PAMPs, they undergo maturation, which is characterized by an 
increase in the levels of surface MHCII and an upregulation of costimulatory molecule 
expression6,7.    While  antigen  uptake  is  downregulated  upon  maturation,  migration  is 
increased,  allowing  the  DCs  to  rapidly  home  to  LNs  where  they  can  induce 
downstream T cell activation.  Although it is clear that inflammatory, fully mature DCs 
induce immunity rather than tolerance, there is not complete consensus in the field as 
to which type of DCs is ideal for inducing tolerance.  Previously, it has been held that 
immature DCs are the most appropriate to induce tolerance, since their role in steady-
state settings is to maintain peripheral tolerance.  However, this is in conflict with the 
fact that completely immature DCs do not effectively present antigen or migrate to LNs, 
which limits their ability to interact with T cells.  More recently, studies have shown that, 
even in the steady-state, DCs acquire certain features of maturation as they migrate, 
such as higher expression of CCR7, MHCII, and even some costimulatory molecules.  69 
 
Such DCs have been termed semi-mature DCs8, and it has been suggested that these 
DCs  induce  IL-10  producing  regulatory  T  cells,  whereas  immature  DCs  induce  T  cell 
anergy.  In vivo targeting of antigen to immature or semi-mature DCs via endocytic 
receptors such as DEC-205 has been shown to induce deletion or hyporesponsiveness 
of antigen-specific T cells9–12.  In addition, tolerogenic factors may be used to prime DCs 
for  tolerance13,  generating  what  are  termed  tolerogenic  DC  (tolDC)  or  induced 
tolerogenic DC (itDC). 
 
The ability of DCs to induce antigen-specific tolerance has been tested in preclinical 
models  for  several  different  autoimmune  diseases,  including  type  1  diabetes.    Non-
obese diabetic (NOD) mice are the most widely used animal model of type 1 diabetes, 
among several existing models.  Some of the other mouse models, RIP-OVA (ovalbumin) 
and RIP-LCMV (lymphocytic choriomeningitis virus) are immune mediated, but rely on 
the tissue-specific transgenic expression of foreign proteins to raise a cytotoxic immune 
response, thus breaking tolerance and triggering the specific destruction of beta cells.  
NOD mice are seen as the most relevant disease model since diabetes is spontaneously 
occurring, has a genetic association, and bears a number of similarities to human type 
1 diabetes.  In both cases, insulitis, or infiltration of pancreatic islets by lymphocytes, is 
followed by β cell destruction and a loss of insulin secretion14.  Hyperglycemia does not 
occur  until  the  majority  (estimated  to  be  ~90%)  of  beta  cells  have  already  been 
destroyed14.  In both mice and humans, the disease is primarily T cell-driven, implicating 
both CD4+ and CD8+ T cells, but B cells producing auto-antibodies also play a role in 
disease progression14.  Genetic susceptibility to type 1 diabetes is strongly associated 
with specific  MHC  and  HLA alleles  in mice and  humans, respectively, and  structural 70 
 
similarities have been noted between the peptide binding pockets of MHCII I-Ag7 in 
NOD mice and human diabetes-associated HLA alleles15.  As in humans, environmental 
factors affect disease development in NOD mice, as illustrated by differences in disease 
incidence rates among different colonies or facilities. Even within a single colony, the 
age of disease onset varies widely, and some mice never develop overt diabetes. 
 
In  order  to  dissect  the  role  of  T  cells  with  single  antigen  specificities  in  disease 
progression, a number of islet-reactive T cell clones were established from NOD derived 
T cells16.  The TCR α- and β-chain genes from the BDC2.5 CD4+ clone were used to 
generate transgenic mice expressing islet antigen-specific CD4+ T cells17.  While these 
BDC2.5 transgenic mice exhibit a lower incidence of diabetes than NOD mice, BDC2.5 T 
cells clearly have the capacity to be diabetogenic, since adoptive transfer of in vitro 
pre-activated BDC2.5 T cells induces rapid disease progression in young non-diabetic 
NOD  mice18  and  in  NOD-scid  mice19.    On  the  other  hand,  BDC2.5  T  cells  can  also 
develop into functional Tregs, making them  appropriate  for  studies investigating the 
induction of tolerance.  BDC2.5 Tregs that were expanded in vitro by DCs were found to 
be >100-fold more effective at preventing diabetes in pre-diabetic NOD mice upon 
adoptive  transfer  as  compared  to  polyclonal  Tregs  from  NODs20.    In  addition,  these 
same BDC2.5 Tregs were effective therapeutically in NODs with new-onset diabetes, 
leading to long-lasting reversal of hyperglycemia in 50% of the mice21.  In another report, 
BDC2.5 T cells transduced with FoxP3 to endow them with Treg function were able to 
home  to  the  pancreatic  LNs  and  reverse  disease  in  NOD  mice  with  recent-onset 
diabetes,  while  FoxP3-transduced  polyclonal  T  cells  were  unable  to  do  so22.    These 
studies demonstrate not only that antigen specificity is important for Treg function, but 71 
 
also that it is possible for Tregs with a single antigen specificity to effectively suppress 
disease, both in prophylactic and therapeutic settings.  BDC2.5 T cells respond to a 
number of peptide sequences presented in association with the I-Ag7 molecule.  The 
endogenous antigen recognized by BDC2.5 cells was initially unknown, and for some 
time it was thought to identify a peptide derived from Glutamic Acid Decarboxylase 65 
(GAD65)23.    Recently,  the  true  endogenous  peptide  recognized  by  BDC2.5  was 
identified as being derived from Chromogranin A24.  For the studies described in this 
chapter, the high affinity BDC13 peptide mimetope sequence25 was used.  While there 
are many other antigens implicated in diabetes progression, the BDC2.5 system is highly 
useful for elucidating mechanisms of antigen-specific T cell responses in NOD mice. 
 
In this chapter, the sub-hypothesis is that the material system developed in Chapter 2 
can, in addition to effectively recruiting DCs, present the DCs with a peptide antigen in 
a  localized  manner  and  redeploy  them  to  the  LNs  to  elicit  antigen-specific  T  cell 
responses.  Here, the NOD model of T1D together with BDC2.5 TCR-transgenic T cells 
were  used  to  study  antigen-specific  responses  that  occur  following  delivery  of  the 
BDC13 (BDC) peptide. 
 
3.2 Materials and Methods 
 
In vivo cell characterization studies 
In vivo cell characterization studies were performed as described in Chapter 2. 
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Flow cytometry 
Flow cytometry was performed as described in Chapter 2. 
 
PLG microsphere fabrication 
Peptide-loaded PLG microspheres were fabricated following the procedure described 
in  Chapter  2,  the  only  difference  being  that  the  BDC  peptide  (AAVRPLWVRMEAA; 
Peptide 2.0 or 21st Century Biochemicals) was dissolved in 100uL of DMSO instead of in 
H2O. 
 
In vitro peptide release 
Peptide-loaded  PLG  particles  were  gas-foamed  into  porous  scaffolds  as  described 
previously26.  The resulting peptide-loaded scaffolds were incubated at 37°C in 1mL of 
release  buffer.    At  the  indicated  timepoints,  the  release  buffer  was  collected  and 
replaced with 1mL of fresh buffer.  The amount of released peptide was quantified by 
peptide ELISA, as described below. 
 
In vivo peptide biodistribution 
Peptide-loaded  scaffolds  were  implanted  subcutaneously  into  the  left  flanks  of 
C57BL/6J mice, as described previously26.  At the indicated timepoints, scaffolds and 
tissue samples were isolated.  Samples were taken from muscle tissue directly underlying 
the material, as well as 4mm, 8mm, and >3cm (i.e. on the right flank) away from the 
implanted material.  The left inguinal and axillary LNs were also isolated.  The scaffold 
was cut into small (~1mm) pieces,  and 500uL of T-Per reagent (Pierce) was used to 
extract  proteins  from  the  tissue  infiltrating  the  scaffold,  following  the  manufacturer’s 73 
 
instructions.    The  pieces  of  polymer,  which  were  insoluble,  were  separated  by 
centrifugation.  Proteins were extracted from the other tissue samples using 500uL of T-
Per  reagent,  as  for  the  scaffolds.    All  samples  were  analyzed  by  peptide  ELISA,  as 
described below. 
 
Peptide ELISA 
To enable detection of full length, non-degraded peptide, biotin and DNP tags were 
incorporated  at  the  N-  and  C-  termini  of  the  peptide,  respectively  (Biotin-
AAVRPLWVRMEAAK(DNP);  Peptide  2.0).    Peptide  was  detected  using  a  customized 
ELISA assay.  StreptaWell (High Bind, Roche) 96 well plates were incubated in blocking 
buffer  (1%  BSA  in  PBS)  at  room  temperature  for  1h,  then  the  blocking  buffer  was 
removed.  50uL of fresh blocking buffer + 50uL of standards or samples (in T-Per reagent) 
were added to the wells and incubated for 1h at room temperature.  The DNP tag on 
the peptide was detected using 100uL of anti-DNP antibody (10ug/mL), followed by 
100uL  of  anti-rat  IgG-HRP  secondary  antibody  (10ug/mL).    Detection  steps  were 
performed by diluting reagents in blocking buffer, incubating at room temperature for 
1h, and washing wells 5 times in wash buffer (0.05% Tween-20 in PBS) in between each 
step.  100uL of a standard ELISA chromogenic substrate (R&D Systems or BioLegend) 
were allowed to develop for 20-30min before the addition of 100uL 1N sulfuric acid stop 
solution.  Plates were read for absorbance at 450nm within 30 min, and absorbance at 
540nm was used for wavelength correction. 
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T cell culture 
Primary T cells isolated from mice were cultured in RPMI-1640 medium (with L-glutamine; 
Sigma Aldrich) supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin, 
10mM  HEPES,  and  50uM  β-mercaptoethanol.    This  T  cell  medium  was  also  used  for 
cocultures of T cells and DCs. 
 
BMDC culture 
Bone marrow cells were isolated using a standard procedure.  Briefly, the femur and 
tibia  bones  were  isolated  and  flushed  with  HBSS  using  a  25G  needle.    Cells  were 
dissociated and filtered through a 40um cell strainer.  For NOD BMDCs, 5 x 106 cells were 
plated in 10mL of medium in bacteriological Petri dishes.  The medium used for BMDC 
differentiation  consisted  of  RPMI-1640  medium  (with  L-glutamine;  Sigma  Aldrich) 
supplemented  with  10%  heat-inactivated  FBS,  1%  penicillin/streptomycin,  50uM  β-
mercaptoethanol, and 20ng/mL GM-CSF.  At day 3, 10mL of fresh medium were added 
to  each  dish,  and  at  day  6,  10mL  of  medium  were  removed  from  each  dish  and 
replaced with 10mL of fresh medium. 
 
In vivo peptide presentation 
Gels were injected subcutaneously into the flanks of NOD/ShiLtJ mice.  At the indicated 
timepoints, gels and LNs were isolated and dissociated, as described for the in vivo cell 
characterization studies.  The cells were resuspended in medium and irradiated with 
5krad to inhibit their proliferation.  Separately, CD4+ T cells were isolated from the spleen 
and lymph nodes of BDC2.5 mice and sorted using an untouched CD4+ MACS sorting 
kit (Miltenyi).  Each of the irradiated cell samples was plated into 6 separate wells of a 75 
 
96  well  plate.    3  wells  per  sample  were  used  for  background  subtraction,  and  105 
BDC2.5 CD4+ T Cells were added to the other 3 wells.  After 48h, 1uCi of 3H-thymidine 
was added to each well. After an 18h pulse, the samples were harvested on a Tomtec 
cell harvester and 3H counts were read using a Microbeta 1450 scintillation counter. 
 
In vivo T cell proliferation 
BDC2.5 T cells were labeled with a cell proliferation dye (CFSE or eFluor 670, eBioscience) 
and  1-2  x  106  cells  were  adoptively  transferred  into  NOD  recipients  i.v.  by  tail  vein 
injection.  One day later, gels delivering peptide were injected.  LNs were isolated at 
various timepoints, and the dilution of the cell proliferation dye was analyzed by flow 
cytometry. 
 
In vivo T cell cytokine secretion 
Gels were injected subcutaneously into the flanks of NOD/ShiLtJ mice.  At the indicated 
timepoints,  LNs  were  isolated  and  dissociated  as  described  for  the  in  vivo  cell 
characterization  studies.    The  samples  were  enriched  for  CD4+  T  cells  using  an 
untouched CD4+ MACS sorting kit (Miltenyi).  The enriched T cells were cocultured with 
7.5 x 104 NOD BMDCs, and 1uM peptide was added for restimulation.  A BMDC culture 
was started 7 days in advance of the coculture according to the procedure described 
above, and 24h before the start of the coculture, 50ng/mL LPS was added to mature 
the BMDCs.  Supernatants from the DC : T cell cocultures were collected after 24h and 
stored at -20°C until cytokine analysis was performed, as described below. 
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qPCR 
Cells  were  stained  for  CD11b,  CD11c,  CD3e,  DX5.    Calcein  blue  (eBioscience)  was 
added  to  a  final  concentration  of  10  uM  to  discriminate  live  cells  and  sorted  on  a 
Beckman  Coulter  MoFlo  Astrios.    RNA  was  extracted  using  TRIzol  reagent  (Life 
Technologies)  according  to  a  standardized  protocol  recommended  by  the 
Immunological  Genome  Project27.    cDNA  was  synthesized  using  the  High  Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems).  The RT-PCR reaction was carried 
out using TaqMan gene expression assays with the TaqMan Fast Advanced Master Mix 
on an ABI 7900 HT Real-Time PCR System (Applied Biosystems). 
 
Cytokine analysis 
Gels  or  cell  culture  supernatants  were  analyzed  by  performing  BioPlex  assays,  using 
either the mouse cytokine 23-plex or 8-plex (Bio-Rad) according to the manufacturer’s 
instructions.  The samples were run on a BioPlex 3D System (Bio-Rad).  To extract proteins 
from gels for cytokine analysis, 500uL of T-Per reagent (Pierce) were added to 100uL gels, 
and protein extraction was performed according to the manufacturer’s instructions. 
 
Statistical analysis 
Statistical analyses were performed as described in Chapter 2. 
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3.3 Results 
 
DCs recruited into pore-forming gels exhibited a non-inflammatory phenotype 
 
The material system that was presented in Chapter 2 demonstrated the ability to recruit 
a significant number and percentage of CD11b+ CD11c+ DCs.  To achieve a better 
understanding of the maturation level of these DCs, a number of cell surface markers 
associated with DC maturation were examined over time (Fig. 3.1).  Over 50% of the 
CD11b+ CD11c+ DCs recruited to the gels expressed MHCII, confirming their status as 
professional APCs (Fig. 3.1 A).  These cells also expressed CD86 (Fig. 3.1 C) and CCR7 
(Fig. 3.1 E), with 30-40% CD86+ cells and ~10-25% CCR7+ cells in gels delivering GM-CSF 
conjugated AuNPs.  At day 3, both the percentage of CD86+ cells, as well as the level 
of  expression  of  the  CD86+  cells,  were  significantly  lower  in  gels  delivering  GM-CSF 
(either GM-CSF alone or GM-CSF + AuNP) compared to control gels (blank or control 
AuNP)  (Fig.  3.1  C-D).    This  trend  was  also  visible  at  day  5,  although  not  all  of  the 
differences  were  statistically  significant.    Over  time,  the  percentage  and  expression 
levels of the CD86+ cells in the control gels decreased and normalized to the levels seen 
in the GM-CSF loaded gels.  For MHCII, a similar trend was seen for the expression levels, 
where the DCs infiltrating the gels delivering GM-CSF expressed significantly less surface 
MHCII compared to the controls at day 3 (Fig. 3.1 B).  As with CD86, the expression of 
MHCII eventually normalized to the same low level for all conditions at later timepoints.  
In terms of the percentage of MHCII+ cells, however, a different trend was observed (Fig. 
3.1 A).  At day 3, gels delivering GM-CSF alone had the highest percentage of MHCII+ 
DCs.  At day 5, the fraction of MHCII+ DCs increased for all conditions.  At days 10 and 78 
 
14,  the  fraction  of  MHCII+  cells  was  maintained  for  the  control  conditions,  but 
decreased significantly in the gels delivering GM-CSF.  CCR7 expression was seen on 
~12% of cells at day 3, and the fraction of CCR7+ cells increased to approximately 20-30% 
at the subsequent timepoints (Fig. 3.1 E-F).  There were no significant differences in the 
percentage or expression levels of CCR7 between conditions. 
 
To further characterize the phenotype of the DCs infiltrating these gels, a number of 
markers  associated  with  different  DC  subsets  were  examined  at  day  3  (Fig.  3.1  G).  
CD11c+ DCs isolated from the gels expressed high levels of the negative costimulatory 
molecules PD-L1 and PD-L2.  Gels delivering GM-CSF + AuNP contained over 90% PD-L1+ 
and ~55% PD-L2+ DCs, which was significantly higher than in the AuNP only control gels.  
At the same timepoint, a significant fraction of CD11c+ DCs also expressed PDCA-1, a 
marker for plasmacytoid dendritic cells (pDCs).  In this case, GM-CSF delivery led to 
reduced PDCA-1 expression, since only ~40% of the DCs in gels delivering GM-CSF were 
PDCA-1+, compared to ~80% in control gels.  A low percentage of DCs expressed the 
endocytic receptor CD205 (DEC-205) (~12%), even fewer expressed CD103 (4-7%), and 
essentially none of the DCs were CD8a+.  In addition, most of the cells were negative for 
CD207 (langerin), a marker of Langerhans cells.  Gels delivering AuNP alone contained 
around 20% CD207+ cells, compared to only 5% in gels delivering GM-CSF.   
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Figure 3.1 (continued).  DCs recruited to the gels exhibited a semi-mature phenotype, 
with low expression of activation markers and high expression of negative costimulatory 
molecules.  Gels  were  injected subcutaneously into  the  flanks  of  C57BL/6J  mice;  at 
specified timepoints, gels were isolated and dissociated to analyze infiltrating cells by 
flow cytometry.  (A-F) Quantification of flow cytometry data showing the percentage 
(A) and MFI (B) of MHCII+ cells, the percentage (C) and MFI (D) of CD86+ cells, and the 
percentage  (E)  and  MFI  (F)  of  CCR7+  cells.    Illustrative  FACS  plots  can  be  found  in 
Appendix C.  (G) Percentage of DCs expressing negative costimulatory molecules (PD-
L1  and  PD-L2)  and  markers  associated  with  various  DC  subtypes  (PDCA-1,  CD207, 
CD205, CD103, and CD8a).  (H-I) Flow cytometry plots comparing cell surface marker 
expression by immature BMDCs (grey) and by cells isolated from gels at day 3 (red, 
overlaid).  (H) Expression of MHCII and CD86.  (I) Expression of PD-L1 and PD-L2.  (n = 3 
per condition per timepoint; mean ± s.d. shown; * p < 0.05; *** p < 0.001; **** p < 0.0001; 
# data not available).   81 
 
Encapsulation of peptide antigen in PLG allowed localized delivery and presentation in 
vivo 
 
The ability of the DCs recruited into the material system to elicit specific T cell responses 
was tested by incorporating the BDC MHCII restricted peptide antigen into the material.  
Encapsulation of peptide in PLG microspheres allowed relatively hydrophobic peptides 
to be readily incorporated into the gel and released gradually.  The release of peptide 
from  PLG  was  first  measured  in  vitro;  for  ease  of  handling,  the  particles  were  gas-
foamed into scaffolds.  Peptide was released at a very slow and sustained rate, with 
only 1.5ug being released over the first week (Fig. 3.2 A).  Next, PLG scaffolds loaded 
with peptide were implanted subcutaneously to examine the distribution of this peptide 
in vivo (Fig. 3.2 B-C).  A variety of tissue samples were analyzed for the presence of 
intact,  i.e.  full-length  and  non-degraded,  peptide.    Intact  peptide  was  consistently 
detected in the tissue infiltrating the scaffold at all assayed timepoints (Fig. 3.2 C).  The 
highest levels, around 100ng, were detected at day 1, followed by fairly constant levels, 
around 20ng, persisting from day 3 to day 14.  However, no peptide could be detected 
in  any  of  the  other  tissues  analyzed,  including  the  muscle  directly  underlying  the 
material and the draining lymph nodes, indicating that the peptide was not diffusing 
into adjacent tissues or passively draining through lymphatic vessels.  Together, these 
results show that a peptide antigen could be delivered at a controlled rate and in a 
highly localized manner, with no detectable spread of the peptide into neighboring 
tissues or into systemic circulation. 
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To determine whether BDC peptide delivered locally from a material in vivo would be 
taken up and functionally presented by DCs, peptide-loaded PLG microspheres were 
incorporated into pore-forming alginate gels delivering GM-CSF.  After subcutaneous 
injection of these gels, the ability of DCs from various tissues to present peptides that 
they acquired in vivo was examined by isolating these DCs and coculturing them with 
BDC2.5 responder T cells.  When OVA, a control peptide, was delivered in the gels, the 
responder T cells did not proliferate, since they did not encounter their cognate antigen 
(Fig. 3.2 D).  In contrast, when BDC peptide was delivered in vivo, the DCs infiltrating the 
gels were clearly able to acquire and present the peptide, as demonstrated by the 
observed responder T cell proliferation (Fig. 3.2 D).  An increase in peptide presentation 
was also seen for DCs isolated from the lymph nodes draining the gels delivering BDC 
peptide, but this difference was not statistically significant.  Peptide presentation was 
not  observed  in  other,  more  distant  lymph  nodes,  supporting  the  notion  that  the 
peptide was not being disseminated systemically.  In the pancreatic LNs, where the 
endogenous antigen from beta cells can be presented by DCs, there appeared to be 
a  small  increase  in  peptide  presentation.    However,  as  for  the  draining  LNs,  this 
difference was not statistically significant. 
 
   83 
 
 
 
        A 
 
        B 
 
C 
 
Figure 3.2.   
8mm 
S   
 
L1     L2   L3 
Skin 
Muscle 
Axilary 
LN 
Inguinal 
LN 84 
 
            D 
 
Figure 3.2 (continued). Sustained delivery of peptide antigen  in vivo led to localized 
antigen presentation in the gel and draining lymph nodes.  (A)  In vitro release of a 
peptide antigen from PLG at 37°C.  (n = 3 per condition per timepoint; mean ± s.d. 
shown).  (B-C) In vivo peptide biodistribution.  (B) Peptide-loaded PLG scaffolds (S) were 
implanted subcutaneously into the left flank.  (C) Peptide was quantified by ELISA at the 
indicated timepoints in various tissues, including the muscle underlying the gel (L1), as 
well as 4mm (L2), 8mm (L3), and >3cm (R) away from the material (n = 4 per condition 
per timepoint; mean ± s.d. shown).  (D) Antigen presentation by APCs isolated from gels 
delivering  GM-CSF  +  AuNP  and  peptide-loaded  PLG  particles,  as  well  as  from  the 
draining  (d),  irrelevant  (i),  cervical  (c),  mesenteric  (m),  and  pancreatic  (p)  LNs,  as 
indicated by the proliferation of BDC2.5 responder T cells.  T cells only, without APCs, 
were used as a negative control (Ø).  (n = 5 per condition per timepoint; mean ± s.d. 
shown). 
 
In vivo delivery of peptide resulted in antigen-specific T cell proliferation and cytokine 
secretion 
 
Delivery  of  peptide  from  the  material  system  in  vivo  led  to  clear  proliferation  and 
expansion of antigen-specific BDC2.5 T cells (Fig. 3.3).  In both control animals that did 
not receive a gel and in animals that received a gel with OVA control peptide, the 
proliferation of adoptively transferred antigen-specific cells was only seen in the pLN, 
where the endogenous peptide from chromogranin A would be found.  In contrast, 
upon delivery of BDC peptide, robust proliferation of the transferred cells was seen in 85 
 
the lymph nodes draining the gel (Fig. 3.3 A).  Proliferating antigen-specific T cells were 
also detected in more distant lymph nodes, but the amount of proliferation was highest 
in the draining lymph nodes, as indicated by a greater extent of CFSE dilution.   
 
An increase in the frequency of adoptively transferred, antigen-specific CD4+ T cells 
was observed in the draining lymph nodes and spleen 5 days after the delivery of BDC 
peptide in the gel system (n.s.) (Fig. 3.3 B).  At day 10, the frequency of tetramer+ T cells 
was significantly higher in the draining lymph nodes of mice that received BDC peptide 
(Fig.  3.3  C).    By  day  20,  the  population  of  antigen-specific  T  cells  found  in  the  LNs 
contracted, returning to baseline levels similar to those in the mice that received OVA 
peptide (Fig. 3.3 D).  Importantly, the expansion of endogenous antigen-specific T cells 
could be detected in NOD mice even without the adoptive transfer of BDC2.5+ T cells 
(Fig. 3.3 E).  The overall frequency of cells detected was lower than when the adoptive 
transfer was performed, but an  increase  in the  frequency of tetramer+  cells was still 
observed for the spleen and dLN (n.s.).   86 
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Figure 3.3 (continued). T cells proliferated and expanded in an antigen-specific manner 
in vivo following delivery of BDC peptide in the material system.  (A) Proliferation of 
adoptively transferred BDC2.5 T cells, as indicated by dilution of the CFSE cell tracking 
dye.    (B-D)  Percentage  of  tetramer+  antigen-specific  T  cells,  which  include  both 
adoptively transferred and endogenous cells, in the draining LNs (dLN), irrelevant (iLN), 
mesenteric (mLN), and pancreatic (pLN) LNs, as well as in the spleen (spl), at days 5 (B), 
10 (C), and 20 (D).  (E) Frequency of endogenous tetramer+ antigen-specific T cells, 
without  any  adoptive  transfer,  at  day  9.    (n  =  1  -  4  per  condition  per  timepoint; 
individual data points and mean shown; **** p < 0.0001; statistical tests comparing BDC 
to control were only performed for the conditions at day 5 where n >= 3). 
 
To define the functional status of the proliferating, antigen-specific T cells in this system, 
CD4+  T  cells  were  isolated  and  restimulated  in  vitro  to  characterize  their  cytokine 
secretion.  Either BDC or OVA (control) peptides were delivered in the material system in 
vivo, and, for each of these conditions, the isolated T cells were restimulated in vitro with 
either BDC or OVA peptides.  In vitro restimulation with the OVA control peptide did not 
lead to cytokine secretion, even for T cells isolated from mice that received OVA in vivo 
(Fig.  3.4  A  &  C).    In  contrast,  restimulation  with  BDC  peptide  did  trigger  cytokine 
secretion in an antigen-specific manner (Fig. 3.4 B & D).  Specifically, T cells isolated 
from the draining LNs of mice that received BDC-loaded gels secreted high levels of IL-2 
upon restimulation with BDC peptide (Fig. 3.4 B).  T cells isolated from other lymph nodes 88 
 
in these same mice also secreted IL-2 in response to restimulation with BDC, but to a 
much lesser extent (Fig. 3.4 B).  Analysis of other pertinent cytokines showed that they 
were also secreted in an antigen-specific manner, only by T cells isolated from mice 
that were injected with gels delivering BDC in vivo (Fig. 3.4 C-D).  The greatest fold 
increase in antigen-specific secretion, around 27-fold, was seen for IL-10 (Fig. 3.4 D).  
IFN-γ exhibited the second highest increase in secretion, with a 16-fold increase, while 
the other cytokines assayed only showed more modest increases between 2- to 8-fold.  
Cells isolated from gels that received OVA in vivo did not exhibit such antigen-specific 
cytokine secretion (Fig. 3.4 C). 
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Figure  3.4  (continued).    T  cells  secreted  cytokines  in  an  antigen-specific  manner 
following delivery of peptide in the gel system.  (A-D) 5 days after administration of gels 
delivering GM-CSF and peptide, T cells were isolated from the draining (dLN), irrelevant 
(iLN), and pancreatic (pLN) lymph nodes.  T cells were restimulated in vitro by BMDCs 
pulsed with either BDC peptide or control peptide (OVA).  Coculture supernatants were 
analyzed to determine the cytokine secretion profile of the T cells.  (A-B) IL-2 secretion 
by T cells isolated from mice that received control OVA peptide-loaded gels (A) or BDC 
peptide-loaded gels (B) in vivo.  (C-D) Secretion of cytokines associated with Th1, Th2, 
Th17,  and  Treg  phenotypes  by  T  cells  isolated  from  the  draining  LNs  of  mice  that 
received  OVA  (C)  or  BDC  (D)  in  gels  in  vivo,  represented  as  a  fold  difference  in 
secretion between BDC restimulation and OVA restimulation.  (n = 3; mean ± s.d. shown; 
# data out of range). 
 
Incorporation of PLG particles in pore-forming gels altered the phenotype of recruited 
DCs 
 
The impact of using PLG as a vehicle for delivering peptide on the phenotype of cells 
recruited  into  the  material  system  was  investigated.    In  gels  delivering  GM-CSF 
conjugated  to  AuNPs,  either  with  or  without  PLG  particles,  >~95%  of  the  cells  were 
consistently CD11b+ across all timepoints (Fig. 3.5 A).  However, substantial differences in 
expression were seen for the other markers assayed.  In gels that recruited DCs using 
only GM-CSF conjugated to AuNPs, the percentage of CD11c+ (Fig. 3.5 B), F4/80+ (Fig. 90 
 
3.5 C), and MHCII+ (Fig. 3.5 D) cells was initially low at day 1, but these populations 
increased significantly at days 3 and 5.  In contrast, for gels also delivering  peptide-
loaded PLG particles, the fraction of these cell populations started at similar low levels 
at  day  1,  but  failed  to  increase  substantially  over  time.    The  fraction  of  F4/80+  and 
MHCII+ cells remained almost the same as at day 1, and the CD11c+ population only 
showed a modest increase.  At day 5, gels delivering PLG and peptide contained 3.5-
fold,  28-fold,  and  12-fold  lower  fractions  of  CD11c+,  F4/80+,  and  MHCII+  cells, 
respectively.  Intriguingly, the opposite trend was seen for Gr-1+ cells (Fig. 3.5 E).  At day 
1, around 90% of the cells were Gr-1+, in addition to being CD11b+, for both conditions.  
At  subsequent  timepoints,  the  fraction  of  Gr-1+  cells  decreased  significantly  in  gels 
without PLG particles, reaching less than 5% at day 5.  In gels with PLG, the population 
of Gr-1+ cells remained higher than 90% through day 5, at which point the fraction of 
Gr-1+ cells was 20-fold higher than in gels without PLG. 
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Figure 3.5 (continued). Incorporation of PLG particles in the gels significantly altered the 
phenotype of cells recruited in response to GM-CSF.  Gels delivering GM-CSF, either 
with  or  without  peptide-loaded  PLG  particles,  were  injected  subcutaneously  in  the 
flanks of C57BL/6J mice; at specified timepoints, gels were isolated and dissociated to 
analyze infiltrating cells by flow cytometry.  (A-E) Percentage of cells expressing CD11b+ 
(A),  CD11c+  (B),  F4/80+  (C),  MHCII+  (D),  and  Gr-1+  (E).    (F-G)  Flow  cytometry  plots 
showing  expression  of  CD11c  and  Gr-1  by  cells  isolated  from  gels  delivering  only 
AuNP/GM-CSF (F) or AuNP/GM-CSF with peptide-loaded PLG particles (G) at 5 days.  (n 
= 3; mean ± s.d. shown; * p < 0.05; **** p < 0.0001). 
 
Higher levels of inflammatory cytokines were expressed in gels containing PLG particles 
 
To  further  assess  the  maturation  status  of  the  cells  in  the  gels,  the  expression  of 
inflammatory cytokines was examined at both the mRNA and protein levels at day 3, 
the peak of cell infiltration.  For gene expression analysis, live cells were sorted on the 
basis of CD11b and CD11c to separate CD11b+ CD11c+ double positive “DCs” from 
CD11b+ CD11c- single positive “myeloid” cells (Fig. 3.6 A).  The cells that did not fit into 
those  populations,  i.e.  lymphocytes  (CD3e+  and  DX5+  cells)  and  CD11b-  cells,  were 
pooled together and excluded.  Splenocytes from naïve mice were used as a basis for 
comparison, and these cells were also separated into different populations using the 93 
 
same sorting strategy (Fig. 3.6  A).  The CD11b+ CD11c+ splenic DCs were used as a 
control representing immature DCs, and all other samples were normalized to this one.  
As a positive control for inflammatory DCs, CD11b+ CD11c+ splenic DCs were stimulated 
with  LPS  for  4h.    As  expected,  the  LPS-stimulated  splenocytes  showed  a  significant 
increase in the expression of transcripts for the inflammatory cytokines, such as Il23a, Il27, 
Il33,  and  Il6.    Expression  of  Il12b  and  Il1a  was  also  increased  in  the  LPS-stimulated 
controls, but not in a statistically significant manner (Fig. 3.6 B).  Cells isolated from gels 
delivering GM-CSF exhibited similar or lower expression levels for all the assayed genes, 
as compared to the immature CD11b+ CD11c+ splenocyte controls (Fig. 3.6 C-D).  Some 
of the transcripts, such as Il12b, were several orders of magnitude less abundant than in 
the splenic DC control.  In cells isolated from gels delivering peptide-loaded PLG, the 
expression  levels  were  also  lower  than  in  the  splenic  DCs  for  many  of  the  genes.  
However,  Il1a  expression  was  significantly  increased  when  peptide-loaded  PLG 
particles were present in the gels (Fig. 3.6 C-D).  Within each experimental condition, 
comparing the CD11b+ CD11c- “myeloid” cells and the CD11b+ CD11c+ “DCs” did not 
reveal  any  significant  differences  in  gene  expression  for  the  transcripts  that  were 
examined here. 
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Figure 3.6 (continued).  Cells in gels containing peptide-loaded PLG particles expressed 
higher  levels  of  Il1a  mRNA.    Gene  expression  analysis  of  cells  isolated  from  gels 
delivering GM-CSF with or without peptide-loaded PLG particles.  Gels were injected 
subcutaneously into the flanks of C57BL/6J mice; after 3 days, gels were isolated, cells 
were sorted, and gene expression was analyzed by qPCR.  (A) Cell sorting strategy to 
separate CD11b+ CD11c- “myeloid” cells from CD11b+ CD11c+ “DCs” for analysis.  (B-D) 
Fold  differences  in  gene  expression,  normalized  to  splenic  DC  controls.    (B)  Control 
splenocytes before or after 4h LPS stimulation.  (C-D) Comparison of gene expression in 
cells isolated from gels either with or without peptide-loaded PLG particles.  The CD11b+ 
CD11c- “myeloid” (C) and CD11b+ CD11c+ “DC” (D) subsets were analyzed separately.  
(n = 3; mean ± s.e.m. shown; **** p < 0.0001). 
 
A  BioPlex  assay  was  performed  to  examine  the  expression  of  a  broad  panel  of 
immunologically relevant cytokines and growth factors (Fig. 3.7).  An overview of all 23 
cytokines assayed revealed  that the  gels contained  very low levels of inflammatory 
cytokines that induce Th1 (i.e. IL-12p70 and IFN-γ) or Th17 (i.e. IL-6) responses, as well as 
low  levels  of  IL-10  and  Th2-inducing  cytokines  (i.e.  IL-4,  IL-13)  (Fig.  3.7  A).    The 
concentrations of some of the assayed cytokines were near or below the lower limit of 
detection.  The most abundant proteins detected in this panel were chemokine (C-C 
motif)  ligand  3  (CCL3  or  MIP-1a),  followed  by  GM-CSF.    Several  other  CC  family 96 
 
chemokines were also expressed, such as CCL4 (MIP-1b), CCL2 (MCP-1), CCL5 (RANTES), 
and  CCL11  (eotaxin).  IL-12p40  and IL-1b were  detectable, but at low levels.   As a 
positive control for inflammatory conditions, LPS was incorporated into gels delivering 
GM-CSF, which resulted in a substantial and expected increase in the production of 
several inflammatory cytokines.  Gels containing peptide-loaded PLG particles did not 
exhibit significant differences in the quantity of inflammatory cytokines detected, as 
compared to AuNP/GM-CSF gels (Fig. 3.7 B-D).  However, gels containing control (i.e. 
blank) PLG particles exhibited levels of inflammatory cytokines that were significantly 
higher than in the gels only delivering GM-CSF.  For IL-12p70 (Fig. 3.7 B) and IL-1b (Fig. 
3.7 D), this increase was statistically significant, whereas for IL-1a (Fig. 3.7 C), the same 
trend was observed, but was not statistically significant.  For all of these cytokines, the 
levels  found  in  gels  delivering  control  PLG  particles  still  remained  lower  than  in  the 
inflammatory LPS control. 
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Figure 3.7 (continued). Gels containing blank PLG particles, but not peptide-loaded PLG 
particles,  expressed  higher  levels  of  inflammatory  cytokines  than  gels  without  PLG 
particles.  Gels were injected subcutaneously in the flanks of C57BL/6J mice; at day 3, 
gels  were  isolated  and  subjected  to  protein  extraction  for  cytokine  analysis.    (A) 
Overview of 23 different cytokines measured in gels delivering GM-CSF conjugated to 
AuNPs.  (B-D) Concentrations of the inflammatory cytokines IL-12p70 (B), IL-1a (C), and 
IL-1b (D) in gels delivering either AuNP/GM-CSF alone, or AuNP/GM-CSF together with 
blank PLG particles or peptide-loaded PLG particles.  Gels delivering AuNP/GM-CSF + 
3ug LPS were used as a positive control for inflammatory conditions.  (n = 3; mean ± s.d. 
shown; * p < 0.05; *** p < 0.001; **** p < 0.0001; AuNP/GM-CSF condition was compared 
to all other conditions.)   98 
 
3.4 Discussion 
 
The material system described in Chapter 2 achieved effective recruitment of millions of 
CD11b+ CD11c+ DCs.  In this chapter, further characterization revealed that these DCs 
exhibited  a  cell surface  marker phenotype consistent with  immature or  semi-mature 
DCs.    To  harness  the  potential  of  these  DCs  to  induce  antigen-specific  T  cells,  the 
material system was further adapted to deliver a defined peptide antigen at a slow 
rate,  which  resulted  in  localized  delivery.    DCs  were  found  to  present  peptide  in  a 
localized manner, which elicited antigen-specific CD4+ T cell proliferation and cytokine 
secretion in the draining LNs.  However, the use of PLG particles to deliver the peptide 
antigen significantly altered the phenotype of the recruited cells, leading to a much 
lower abundance of CD11b+ CD11c+ DCs and an increase in cytokines associated with 
inflammation. 
 
The  CD11c+  DCs  recruited  to  the  material  system  in  response  to  GM-CSF  delivery 
expressed MHCII, CD86, and CCR7, but at relatively low levels, suggesting that they 
were  immature  or  semi-mature.    When  expressed  at  high  levels,  these  markers  are 
indicative  of  DC  maturation.    However,  some  level  of  MHCII  expression  may  be 
important for inducing antigen-specific tolerogenic responses, since MHCII is necessary 
for peptide presentation by DCs to CD4+ T cells.  Similarly, some level of CCR7 expression 
may also be desirable, since CCR7 mediates homing to the lymph nodes, where the 
DCs interact with T cells.  Interestingly, CD86 expression levels were significantly lower in 
gels delivering GM-CSF, either with or without AuNPs, compared to gels without GM-CSF, 
suggesting that GM-CSF may be suppressing maturation.  The levels of MHCII and CD86 99 
 
expressed  on cells recruited  into gels  delivering  GM-CSF  were  comparable  to  those 
seen on immature BMDCs. 
 
Despite  a  thorough  characterization  of  the  cell  surface  markers  expressed  by  DCs 
recruited  using  this  system,  the  specific  subtype  and  lineage  of  these  cells  remains 
unclear.  These DCs were found to express high levels of PD-L1 and PD-L2, two negative 
costimulatory  molecules  that  signal  through  PD-1  on  T  cells  and  are  important  for 
tolerance mechanisms28,29.  This is a promising indication that the DCs infiltrating the gels 
may have the capacity to induce tolerance.  On the other hand, only ~12% of the DCs 
in  this  system  expressed  DEC-205  (CD205),  an  endocytic  receptor  that  has  been 
associated with DCs that have tolerogenic potential30.  A significant fraction of the cells 
consisted  of  PDCA-1+  cells,  which  was  unexpected  since  PDCA-1+  pDCs  are  usually 
described  as  expressing  low  levels  of  CD11c31.    CD8a+  DCs,  which  are  particularly 
effective at cross-presentation and may not be the best targets for modulating CD4+ 
cells32, were not present in this system.  Few of the DCs expressed CD207, i.e. langerin, or 
CD103, two markers found on dermal DCs.  This suggests that, despite the fact that the 
gels were injected subcutaneously and were adjacent to the dermis, the majority of 
DCs infiltrating the gels did not consist of specialized dermal DCs known as Langerhans 
cells.  Gels delivering control AuNPs, without GM-CSF, contained a higher percentage 
of CD207+ cells, which was likely a reflection of the fact that the total number of cells in 
those gels was significantly lower, so the same number of CD207+ would represent a 
greater fraction of the total cells.  It is speculated that the DCs in this material system 
may  be  CD11b+  CD103-  migratory  DCs  or  monocyte-derived  DCs  that  would  have 
migrated,  differentiated,  and  proliferated  in  response  to  GM-CSF.    However, 100 
 
determining the lineage of these cells with certainty would require extensive studies that 
are beyond the scope of this work. 
 
A  peptide  antigen  was  incorporated  into  the  material  delivery  system  by  first 
encapsulating it in PLG microspheres, allowing it to be released at a slow and sustained 
rate.  An in vivo biodistribution study detected intact peptide in the tissue infiltrating the 
material delivery system, but not in the adjacent tissue.  Despite the fact that molecules 
and particles under ~100-200nm33–35 can be passively transported through lymphatic 
vessels, the delivered peptide antigen was also not detected in the LNs draining the 
material.  This precise localization at the site of the material may be explained by the 
fact that the peptide was released at a very slow rate from the material, such that free 
peptide  would  be  either  captured  by  DCs  or  proteolytically  degraded  before  it 
reached  other  tissues.    An  assay  for  peptide  presentation  determined  that  DCs 
recruited to the material system were able to capture the peptide antigen in vivo and 
functionally  present  it  to  T  cells.    Clear  peptide  presentation  was  observed  for  cells 
isolated from the gels, and an increase, although not statistically significant, was also 
seen in the dLN.  Together, these data suggest that only cells infiltrating the material 
were exposed to a local concentration of peptide within the material, allowing them to 
acquire the peptide and transport it to the draining LNs.  The ability to deliver peptide in 
a localized manner is an important feature from a safety perspective, since it eliminates 
the risk of antigen being disseminated to a site of disease where it could potentially 
precipitate  or  exacerbate  autoimmunity3.    In  addition,  maintaining  a  local 
concentration  of  peptide  exclusively  within  the  material  would  be  desirable  if 101 
 
tolerogenic factors were added to this system, since DCs would only be exposed to the 
peptide in the context of tolerogenic signals. 
 
As  a  result  of  in  vivo  peptide  presentation  by  DCs,  CD4+  T  cells  proliferated  and 
expanded  in  an  antigen-specific  manner.    This  was  shown  both  for  adoptively 
transferred BDC2.5 T cells, as well as for endogenous antigen-specific T cells.  Although 
peptide presentation by DCs remained localized to the material and the draining LNs, 
proliferating antigen-specific T cells were found not only in the draining LNs, but also in 
the spleen and other LNs.  The use of a cell proliferation dye showed that the T cells in 
the  draining  LNs  underwent  a  greater  number  of  divisions  than  those  in  the  other 
lymphoid organs, strongly suggesting that the  T cells proliferated upon contact with 
peptide-bearing DCs in the draining LNs and subsequently trafficked to other tissues.  
These  results  demonstrate  that  DCs  programmed  by  a  biomaterial  in  a  localized 
manner interacted with antigen-specific T cells that were able to traffic systemically 
and could potentially home to sites of disease. 
 
After an initial expansion, the population of antigen-specific T cells found in the LNs 
contracted back to baseline levels.  One possibility is that these cells simply died after 
an initial proliferation phase.  Other studies showing a similar effect have attributed this 
to an active T cell deletion process11,36.  In this system, the antigen-specific T cells did not 
disappear completely, suggesting that deletion was not the cause of the population 
contraction,  or  that  any  deletion  that  may  have  occurred  was  incomplete.  
Mechanistic studies would be required to determine whether active deletion, rather 
than simple apoptosis, is playing any role.  Another interesting possibility is that these 102 
 
expanded antigen-specific T cells may have migrated into peripheral tissues.  Although 
the antigen-specific cells did not accumulate in the pancreatic LNs, it is possible that 
some  of  these  T  cells  may  have  homed  to  the  pancreatic  islets,  where  their 
endogenous antigen is found.  The islets themselves were not examined in this set of 
studies,  but  antigen-specific  T  cells  infiltrating  the  islets  could  be  analyzed  by  flow 
cytometry or by immunohistochemistry, both of which would be associated with some 
technical challenges. 
 
In addition to undergoing proliferation, T cells also secreted cytokines in an antigen-
specific  manner  following  the  administration  of  gels  delivering  BDC  peptide.    In 
agreement with the observed T cell proliferation, cells from the draining LNs secreted 
high levels of IL-2 in response to restimulation with BDC peptide.  Other cytokines were 
also secreted in an antigen specific manner, in particular IL-10 and IFN-γ, which are 
suggestive of a Tr1 secretion profile38.  Importantly, restimulation with OVA, which was 
used here as a control peptide, did not induce cytokine secretion, even in the T cells 
isolated from mice that received gels delivering OVA peptide in vivo.  This demonstrates 
that, even though OVA(323-339) can be presented on the I-Ag7 molecule37, this material 
system did not raise immunity towards OVA, which is a foreign peptide. 
 
Upon investigation, it was found that incorporating PLG microspheres into the gels led 
to significant differences in the phenotype of the cells recruited to the gels, as well as 
the expression of cytokines by these cells.  When PLG microspheres were introduced 
into the gels, the majority of recruited cells were still CD11b+ myeloid cells.  However, a 
significantly lower fraction of cells expressed  the  DC-associated marker CD11c, and 103 
 
even  greater  reductions  in  expression  were  seen  for  MHCII  and  F4/80.    The  low 
abundance of CD11c+ and MHCII+ cells indicated that only a small fraction of these 
cells  were  DCs  and  that  they  may  have  a  more  limited ability  to  present  delivered 
antigens.  Gr-1, which labels monocytes and granulocytes, appeared to vary inversely 
with CD11c.  In gels delivering GM-CSF without PLG, the fraction of Gr-1+ was high at 
day  1,  but  decreased  at  subsequent  timepoints  as  the  fraction  of  CD11c+  cells 
increased.  In gels with PLG particles, the percentage of Gr-1+ cells remained high for all 
the timepoints examined.  It is unclear what the functional differences were between 
the  CD11b+  CD11c+  cells  and  the  CD11c+  Gr-1+  cells  seen  in  the  presence  of  PLG 
particles.  In spite of the low frequency of CD11c+ MHCII+ cells found in gels delivering 
peptide-loaded PLG particles, clear antigen-specific T cell proliferation was observed in 
vivo, indicating that, even in the presence of PLG, at least some of the recruited cells 
were competent to present antigen to T cells. 
 
When  PLG  particles  were  incorporated  into  the  gels,  the  recruited  cells  expressed 
higher levels of cytokines associated with inflammation at both the mRNA and protein 
levels.    Strikingly,  cells  isolated  from  gels  delivering  only  GM-CSF  expressed  similar  or 
lower  levels  of  many  genes  encoding  inflammatory  cytokines  as  compared  to 
immature CD11b+ CD11c+ splenic DCs, which were used as a control cell population.  
When  PLG  particles  containing  peptide  were  delivered  in  addition  to  GM-CSF,  Il1a 
expression  was  significantly increased.  It was interesting  to observe  that the  overall 
pattern  of  gene  expression  was  similar  between  the  sorted  CD11c-  “myeloid”  and 
CD11c+ “DC” populations. 
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At  the  protein  level,  gels  delivering  GM-CSF  conjugated  to  AuNPs  exhibited  low  or 
undetectable levels of most inflammatory cytokines, but they did contain a number of 
different CC family chemokines.  Surprisingly, CCL3 (MIP-1a) was the most abundant 
protein  detected  in  gels  delivering  GM-CSF,  even  though  the  abundance  of  Ccl3 
mRNA was several fold lower than in control splenocytes.  The incorporation of peptide-
loaded  PLG  particles  did  not  have  a  significant  impact  on  the  production  of 
inflammatory cytokines in the  gels.  In contrast, incorporation of blank PLG particles 
significantly increased the levels of IL-1b and IL-12p70 protein, with a similar trend also 
seen for IL-1a.  This difference between peptide-loaded and blank PLG particles could 
be attributed to the fact that PLG is known to mediate non-specific protein adsorption, 
which  may  be  greatly  reduced  when  peptide  is  incorporated  into  the  particles.  
However, this raises questions about effects that may occur at later timepoints, as the 
peptide diffuses out of the particles.  Another point of consideration is that the cells 
within the gels were lysed, so these data are not necessarily representative of protein 
secretion.  In addition, some cytokines, like IL-1b, are secreted in an inactive precursor 
form (pro-IL-1b).  Since the BioPlex assay used here was not designed to exclusively 
detect the mature forms of proteins like IL-1a and IL-1b, it is assumed that there could 
be cross-reactivity with their precursor forms (pro-IL-1a and pro-IL-1b). 
 
Taken together, the gene and protein expression data demonstrate that the delivery of 
PLG  microspheres  had  a  significant  impact  on  cell  phenotype,  even  though  the 
particles were encapsulated in the alginate hydrogel.  The changes in cell phenotype 
and  the  increases  in  inflammatory  cytokine  expression  were  consistent  with  the 
qualitative  observations  that  gels  containing  peptide-loaded  PLG  particles  became 105 
 
vascularized in a 5-10 day timeframe and were surrounded by a thickened capsule, 
which was not the case for gels delivering only GM-CSF conjugated to AuNPs.  The 
differences in cytokine expression seen here, while statistically significant, were not as 
drastic as might have been expected based on the stark differences in cell surface 
marker  expression.    The  gels  were  analyzed  3  days  after  injection  because  this 
represented the peak of cell infiltration for gels delivering GM-CSF, but this may not be 
the timepoint at which the differences in cytokine expression are the most pronounced.  
However,  the  observed  differences  in  cell  phenotype  and  the  shift  in  cytokine 
expression may impact the function of the recruited DCs in ways that alter their ability 
to induce tolerogenic responses. 
 
While peptide delivery from PLG microspheres in alginate gels demonstrated desirable 
characteristics of localized delivery and functional antigen presentation by DCs, further 
optimization  will  likely  be  required  to  enable  the  induction  of  robust  tolerogenic 
responses.  In particular, devising a different strategy for localized delivery of peptide 
from the biomaterial may be a promising next step. 
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Chapter 4. Conjugation of a peptide antigen to alginate represents a promising 
delivery strategy for generating antigen-specific tolerogenic responses in vivo 
 
4.1 Introduction 
 
The  spatio-temporal  presentation,  dose,  and  affinity  of  a  peptide  antigen  play  an 
important role in directing immune responses, in addition to the critical signals provided 
by damage associated molecular patterns (DAMPs), pathogen associated molecular 
patterns (PAMPs), and various cytokines.  The notion that strong immune responses are 
elicited when there is a temporal difference, or discontinuity, in the appearance of an 
antigen has been modeled and formulated into a “discontinuity theory” of immunity1.  
This theory captures the phenomena that an invading pathogen is associated with the 
acute introduction of a foreign antigen, potentially at high local concentrations, and 
that  the  successful  elimination  of  an  infection  by  the  immune  system  removes  the 
source of antigen.  In contrast, the presence of antigens at low but persistent levels 
favors tolerance, as in the steady state.  Accordingly, a materials-based vaccine would 
be most effective at inducing tolerance if it could deliver antigen at a low but sustained 
rate.  This chapter addresses specific Aim 3 of this thesis by developing a technique for 
localized  and  cell-triggered  delivery  of  peptide  to  DCs  that  infiltrate  the  non-
inflammatory material system characterized in Chapters 2 and 3. 
 
Several  studies  have  investigated  experimentally  the  effects  of  peptide  dose  and 
affinity  on  the  induction  of  Tregs2–7.    Two  separate  studies  found  that  low  doses  of 
peptide antigen presented by DC in vitro were far more effective than high doses at 111 
 
inducing and expanding suppressive Foxp3+ Tregs in mouse3 and human4 T cells.  The 
doses considered to be “low” varied by 3-4 orders of magnitude depending on affinity 
of the peptide mimetopes3.  Taking this further, in vivo studies found that low doses of a 
high affinity antigen induced FoxP3+ Tregs5,6, while high doses of a low affinity antigen 
induced deletion of the antigen-specific cells after an initial proliferation6.  The FoxP3+ 
Tregs induced by in vivo delivery of low dose, high-affinity peptide were shown to be 
functional, since they were able to prevent disease in the NOD model of T1D7.  Together, 
these studies highlight the importance of regulating peptide dose and presentation for 
the induction of tolerance. 
 
In view of the findings described in Chapter 3, a method was sought to localize the 
delivery of peptide in vivo by covalently coupling it directly to alginate, thus avoiding 
the use any additional material that might cause phenotypic changes in the recruited 
DCs.  As part of this strategy, it was necessary to incorporate a mechanism by which 
the peptide antigen could be released from the material to be loaded onto MHCII 
molecules and presented by DCs to T cells.  A number of biocompatible degradable 
linkers  have  been  characterized  and  used  in  the  field  of  bioengineering.    Several 
different  types  of  linkers  simply  rely  on  the  gradual  breaking  of  chemical  bonds, 
including hydrolytically labile bonds such as esters, acid-labile acetal linkers8, or dithiol 
bonds that are cleaved in biological settings in the presence of glutathione9.  For the 
particular application investigated here, the most appropriate strategy was to engineer 
cell-triggered  degradation  of  the  linker,  such  that  release  of  peptide  would  be 
coordinated  with  cell  infiltration,  allowing  effective  capture  of  the  peptide  by  the 
recruited DCs.  Among the enzymes present in vivo, matrix metalloproteinases (MMPs) 112 
 
are particularly good candidates to mediate cell-triggered release.  MMPs are a family 
of  proteases  used  by  cells  to  degrade  a  wide  variety  of  extracellular  matrix  (ECM) 
proteins, including many types of collagen, as well as fibronectin, laminin, elastin, and 
aggrecan;  as  a  result,  MMPs  are  critical  for  cell  migration  and  tissue  remodeling10.  
MMPs  are  also  important  for  modifying  a  number  of  other  bioactive  molecules, 
performing  functions  such  as  cleaving  cell  surface  receptors  or  activating 
chemokines/cytokines, thus affecting other important cell functions such as proliferation 
and differentiation10.  Many different cell types express different MMPs, and, in particular, 
dermal DCs were shown to express MMP-9 and MMP-2 on their cell surface, which are 
important for their migration through the dermis11.  MMP-cleavable peptide sequences 
have  been  incorporated  into  several  types  of  synthetic  hydrogels,  creating  cell-
degradable  matrices  that  deliver  bioactive  factors12–14  and/or  cells15  for  tissue 
engineering applications.  A number of peptide sequences with different specificities 
and cleavage kinetics have been characterized and optimized to act as substrates for 
different MMPs16,17. 
 
The sub-hypothesis tested in this Chapter was that a defined peptide antigen could be 
coupled to and delivered from the hydrogel system for localized uptake by DCs in a 
non-inflammatory environment.  An MMP-cleavable peptide sequence was selected to 
enable cell-triggered release of the covalently coupled peptide from alginate, allowing 
DCs to present the peptide and induce antigen-specific T cell responses. 
 
   113 
 
4.2 Materials and Methods 
 
In vivo MMP activity assay 
Gels were injected subcutaneously in the flanks of NOD/ShiLtJ mice.  4 days later, 10uL 
of MMPSense 750 FAST (Perkin Elmer) were injected directly into the middle of the gels 
using  27G  needles.    As  recommended  by  the  manufacturer,  baseline  images  were 
taken before injection of the MMPSense reagent, and mice were imaged again 4h 
after  injection.    Fluorescent  in  vivo  imaging  was  performed  using  an  IVIS  Spectrum 
system (Perkin Elmer), and images were analyzed using Living Image software (Perkin 
Elmer). 
 
Alginate conjugation and characterization 
BDC-CMR  peptide  (CGGDDDDGPQGIWGQAAVRPLWVRMEAAKK(Rho_B);  Peptide  2.0) 
was mixed at a 1:1:1 molar ratio with heterobifunctional (maleimide and amine) 7.5kDa 
PEG (JenKem Technology USA) and tris(2-carboxyethyl)phosphine (TCEP) in DMSO.  The 
DMSO solvent was removed and the peptide-PEG conjugate was resuspended in H2O.  
Coupling of the amine on the PEG to alginate was performed using EDC/Sulfo-NHS as 
described previously18.  Peptide coupling was assayed by measuring the absorbance 
and/or fluorescence of the rhodamine B label using a BioTek plate reader. 
 
In vitro peptide presentation 
Bone marrow cells from NOD mice were isolated and differentiated as described in 
Chapter 3.  On day 6 of the BMDC culture, 50ng/mL LPS was added to mature the 
BMDCs for 24h.  On day 7, CD4+ T cells were isolated from the spleen and lymph nodes 114 
 
of  BDC2.5  mice  and  sorted  using  an  untouched  CD4+  MACS  sorting  kit  (Miltenyi).  
Cocultures were set up by plating 105 BDC2.5 CD4+ T cells and 2.5 104 BMDCs per well in 
96 well plates.  The indicated concentrations of BDC peptide or peptide-conjugated 
alginate were added in a total volume of 250uL/well.  The proliferation of the BDC2.5 T 
cells  was  analyzed  after  3  days.  As  a  positive  control  for  proliferation,  T  cells  were 
cultured at a 1:4 ratio with mouse anti- CD3/CD28 activation beads (Dynabeads, Life 
Technologies). 
 
In vivo peptide presentation 
In vivo peptide presentation assays were performed as described in Chapter 3. 
 
In vivo cell characterization studies 
In vivo cell characterization studies were performed as described in Chapter 2. 
 
Flow cytometry 
Flow cytometry was performed as described in Chapter 2. 
 
Statistical analysis 
Statistical analyses were performed as described in Chapter 2. 
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4.3 Results 
 
A peptide antigen was covalently coupled to alginate for localized delivery and cell-
triggered release 
 
First, to determine whether the DCs recruited to the material system would be able to 
degrade  an  MMP-cleavable  linker  and  mediate  release  of  covalently  conjugated 
peptide, MMP activity in the gels was assayed in vivo.  A fluorogenic MMP substrate was 
injected directly into the gels around the peak of DC infiltration.  Gels delivering GM-
CSF exhibited significantly enhanced MMP activity in vivo compared to control gels (Fig. 
4.1), validating the use of an MMP-cleavable linker to mediate release of a covalently 
coupled peptide antigen from the alginate gels. 
 
A              B 
      
Figure 4.1.  Pore-forming alginate gels delivering GM-CSF exhibited higher MMP activity 
than control gels.  AuNP control gels and gels delivering GM-CSF + AuNPs were injected 
subcutaneously in the left and right flanks, respectively, of NOD/ShiLtJ mice.  (A) 4 days 
after administration of the gels, a fluorogenic MMP substrate was injected directly into 
the gels and 3 replicate mice were imaged.  (B) Quantification of the image shown in 
(A).  Regions of interest (ROIs) of the same size were centered over each gel for analysis 
of the fluorescent signal.  (n = 3; mean ± s.d. shown; ** p < 0.01.)   116 
 
The BDC peptide antigen was modified to  include an N-terminal cysteine  for use in 
coupling  reactions,  followed  by  a  short  linker  and  an  MMP-cleavable  peptide 
sequence, as well as a C-terminal Rhodamine B label for detection (Fig. 4.2 A).  This 
modified version of the BDC peptide was termed BDC-CMR (cysteine, MMP-cleavable, 
Rhodamine).    Despite  the  addition  of  aspartic  acid  residues  in  the  linker  region  to 
increase  the  hydrophilicity  of  the  BDC-CMR  peptide,  it  only  dissolved  in  water  to  a 
concentration  of  2.8  mg/mL  (Fig.  4.2  B).    To  make  the  peptide  more  amenable  for 
aqueous coupling chemistries, a 7.5kDa heterobifunctional polyethylene glycol (PEG) 
chain was conjugated to the BDC-CMR peptide to increase its solubility in water.  After 
reacting  the  maleimide  on  the  PEG  with  the  cysteine  on  the  peptide,  the  resulting 
peptide-PEG conjugate was soluble in water at a concentration of at least 5mg/mL (Fig. 
4.2  B).    The  peptide-PEG  conjugate  was  then  coupled  to  alginate  using  standard 
EDC/NHS chemistry.  The coupling efficiency, which was determined by quantifying the 
rhodamine label on the peptide, was approximately 60% (Fig. 4.2 C). 
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Figure 4.2.  A modified, MMP-cleavable BDC peptide was coupled to alginate polymer 
with an efficiency of 60%.  (A) Strategy for the  multi-step coupling of the BDC-CMR 
peptide to alginate.  (B) Dissolution of the BDC-CMR peptide in water before and after 
conjugation  to  PEG.    Dashed  line  indicates  expected  concentration  (5mg/mL) 
assuming  complete  dissolution  of  the  peptide.    (C)  A  60%  efficiency  of  peptide 
coupling to alginate was determined by measuring the amount of peptide removed 
during dialysis and conjugated to the alginate.   118 
 
Peptide-conjugated alginate mediated functional antigen presentation by DCs in vitro 
and in vivo 
 
The BDC-CMR peptide-modified alginate was tested to determine whether DCs would 
be able to successfully capture and present the peptide both in vitro and in vivo (Fig. 
4.3).  In vitro, several doses of polymer were added to a coculture of DCs with BDC2.5 
responder T cells.  The responder T cells proliferated in response to all the tested doses of 
peptide-conjugated  alginate,  demonstrating  that  the  peptide  can  be  functionally 
presented (Fig. 4.3 A).  For two of the doses, the proliferation was statistically significantly 
lower than for the equivalent dose of free peptide.  However, for the doses tested here, 
increasing doses of peptide yielded fewer cells at the end of the culture.  In vivo, gels 
were injected subcutaneously and peptide presentation was assayed in a number of 
different  lymph  nodes.    At  day  5,  significant  levels  of  peptide  presentation  were 
detected in the gels, but not in the other LNs assayed (Fig. 4.3 B). 
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Figure  4.3.    Peptide-conjugated  alginate  resulted  in  functional  peptide  presentation 
both in vitro and in vivo.  (A) In vitro proliferation of BDC2.5 T cells in response to soluble 
BDC peptide or BDC-CMR conjugated alginate, after 3 days of coculture with BMDCs 
from NOD/ShiLtJ mice.  Controls consisted of T cells alone (- control) or T cells cultured 
with activation beads (+ control for proliferation).  (n = 3; mean ± s.d. shown; *** p < 
0.001;  ****  p  <  0.0001.)    (B)  Proliferation  of  BDC2.5  T  cells  in  response  to  peptide 
presentation by irradiated APCs isolated 5 days after injection of gels delivering BDC-
CMR in NOD/ShiLtJ mice.  (n = 3 - 4; mean ± s.d. shown; ** p < 0.01.)   120 
 
Delivery of peptide-coupled gels in vivo resulted in antigen-specific T cell responses 
 
Next,  the  effect  of  delivering  peptide-conjugated  alginate  on  T  cells  in  vivo  was 
examined.  Upon delivery of 0.1nmol of BDC-CMR peptide conjugated to alginate gels, 
the  percentage  of  endogenous  tetramer+  CD4+  T  cells  increased  significantly  in  the 
draining LNs at day 5, reaching ~1.2% of the total CD4+ T cells (Fig. 4.4).  While the 
expansion of tetramer+ cells was clearly seen in the draining LNs, the frequency of these 
cells  did  not  increase  in  the  irrelevant  or  pancreatic  lymph  nodes.    At  day  7,  the 
frequency of tetramer+ cells was reduced, but still appeared higher than baseline (n.s.).  
By day 14, the frequency of these tetramer+ decreased even further, returning to levels 
similar to the baseline in naïve mice for all the LNs.  The frequency of tetramer+ cells in 
the  irrelevant  and  pancreatic  LNs  did  not  vary  significantly  over  the  timecourse 
examined. 
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Figure 4.4. Delivery of BDC-CMR peptide in vivo led to the expansion of tetramer+ CD4+ T 
cells.  Gels  were  injected  subcutaneously  into  the  flanks  of  NOD/ShiLtJ  mice;  at 
specified timepoints, gels were isolated and dissociated to analyze infiltrating cells by 
flow cytometry.  (n = 2 - 6; individual data points and mean shown; * p < 0.05; **** p < 
0.0001;  for  each  condition,  the  different  timepoints  were  compared  to  each  other; 
statistical tests were only performed for the conditions where n >= 3.) 
 
Gels delivering peptide antigen locally contained a high percentage and number of 
antigen-specific FoxP3+ cells 
 
The frequency of tetramer+ cells and FoxP3+ cells was examined in the gels delivering 
peptide and in the LNs (Fig. 4.5).  The frequency of T cells in the gels was very low, 
around  ~3%  at  days  3,  5,  and  7  (Fig.  4.5  A).    At  day  14,  the  frequency  of  T  cells 
increased to ~7.2%, but this difference was only statistically significant compared to day 
5.  Although the frequency of T cells was low, the fraction of these T cells that were 
tetramer+  increased  steadily  over  time.    At  days  3,  5,  7,  and  14,  the  frequency  of 
tetramer+ cells were 0.7%, 2.7%, 9.3%, and 27.6%, respectively (Fig. 4.5 B).  The frequency 
of these cells at day 14 was statistically significantly higher than at days 3 and 5.  At day 122 
 
14, the T cells were analyzed for their expression of FoxP3 (Fig. 4.5 C-E).  In the gels, the 
percentage of FoxP3+ cells was significantly higher than in LNs from either naïve mice or 
mice that received gel injections.  This observation held true when FoxP3+ cells were 
analyzed  either  as  a  fraction  of  CD4+  cells  or  as  a  fraction  of  tetramer+  cells.  
Approximately 10-fold more CD4+ T cells were FoxP3+ in the gels (~64%) as compared to 
the LNs (~6%) (Fig. 4.5 C).  When analyzed as a fraction of tetramer+ cells, ~62% of the 
tetramer+ cells in the gels were found to express FoxP3, compared to ~5-14% in the LNs 
(Fig. 4.5 D).  No differences were noted in the frequency of FoxP3+ in the LNs of naïve 
mice and mice that received injections of the material delivery system.  The overall 
number of tetramer+ FoxP3+ cells was calculated by adjusting for total cell number.  The 
gels contained on average ~7,000 antigen-specific FoxP3+ cells, which was 1 to 2 orders 
of magnitude greater than the number of these cells found in the lymph nodes, which 
only contained ~90-500 of these cells (Fig. 4.5 E). 
 
A                   B 
     
Figure 4.5. 
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Figure 4.5 (continued).  Tetramer+ FoxP3+ CD4+ T cells accumulated in gels delivering 
BDC-CMR conjugated to alginate.  Gels were injected subcutaneously in the flanks of 
NOD/ShiLtJ mice; at specified timepoints, gels were isolated and dissociated to analyze 
infiltrating cells by flow cytometry.  The percentage of CD4+ cells (A) and tetramer+ 
CD4+ cells (B) were analyzed.  (n = 2 - 6; individual data points and mean shown; * p < 
0.05; **** p < 0.0001; all conditions were compared to each other; statistical tests were 
only performed for the conditions where n >= 3.)  (C-E) Analysis of the CD4+ cells in the 
gels at day 14, showing the fraction of CD4+ cells that were FoxP3+ (C), the fraction of 
tetramer+ cells that were FoxP3+ (D), and the number of FoxP3+ tetramer+ CD4+ T cells in 
the gels (E), as calculated by adjusting for total cell number.  (n = 3; mean ± s.d. shown; 
** p < 0.01; **** p < 0.0001; all conditions were compared to each other.)   124 
 
4.4 Discussion 
 
In this chapter, a new strategy for delivering a peptide antigen in a localized and cell-
triggered manner was described.  To validate the use of an MMP cleavable sequence 
for triggered release of the peptide, MMP activity in the gels was first assessed.  In vivo 
imaging using a fluorogenic MMP substrate demonstrated that gels delivering GM-CSF 
exhibit significantly higher MMP activity than control gels.  The  apparent increase in 
MMP activity in control gels relative to the surrounding skin was attributed to the higher 
concentration of substrate in the gels compared to the rest of the skin, since the poor 
vascularization of the gels necessitated injection of the substrate directly into the gels 
rather  than  i.v.    Next,  the  BDC-CMR  peptide,  which  consisted  of  the  BDC  peptide 
antigen  with  an  appended  MMP-cleavable  sequence,  was  conjugated  to  PEG  to 
increase  its  solubility  in  water.    The  peptide-PEG  conjugate  was  then  coupled  to 
alginate, and a high coupling efficiency was achieved. 
 
The  ability  of  the  BDC-CMR  peptide-modified  alginate  to  elicit  functional  T  cell 
responses was evaluated, first in vitro.  At all doses of peptide assayed, the peptide 
modified alginate was successful at inducing the proliferation of BDC2.5 responder T 
cells  in  a  coculture  with  BMDCs.    When  comparing  equivalent  doses  of  peptide-
modified alginate to soluble peptide added directly to the media, the number of T cells 
enumerated at the end of the coculture was slightly lower for the peptide-conjugated 
alginate.  This difference may be attributed to the timing of the peptide presentation, 
since the peptide conjugated to alginate requires cleavage by MMPs to be released, 
and as a result it may not be immediately available for loading and presentation on 125 
 
MHCII molecules.  In addition, it must be noted that the range of concentrations tested 
appeared to be higher than the optimal range, since increasing peptide doses resulted 
in a lower number of T cells at the end of the culture period, both for free peptide as 
well  as  for  the  peptide-modified  alginate.    Considering  this,  it  is  possible  that  the 
peptide-conjugated alginate actually resulted in more effective peptide presentation 
by DCs for the same dose of peptide, which would explain why the final number of T 
cells was lower than  for  the  equivalent dose  of free peptide.   In vivo, the  peptide-
modified  alginate  was  also  able  to  be  released  and  presented  by  DCs.    At  day  5, 
peptide was presented in the gels, but not in the other LNs assayed.  It should be noted 
that these data showed a relatively low level of signal, even for the positive controls.  
Further optimization may have been required to detect signal in the draining LNs. 
 
Overall, these in vitro and in vivo results show that using an MMP-cleavable sequence 
to release peptide from a biomaterial allowed functional presentation of the peptideby 
DCs.  This strategy could be used more broadly to deliver different peptide antigens to 
DCs; however, this technique  may require  a  great deal more  optimization  for MHCI 
binding peptides than for MHCII binding peptides, the latter of which were used here.  
Most MMP-cleavable peptides reported in the literature are ~6-8 amino acids long, and, 
after cleavage, a few amino acids remain on either side of the cleavage site.  For 
presentation on MHC class II, the peptide length is not tightly restricted, since the MHCII 
binding pocket is open on both ends, allowing peptides to be bound in a conformation 
where their ends can extend beyond the edges of the binding pocket.  In contrast, 
MHC I peptides are much more restricted in length (8-9 amino acids) and their terminal 
amino acids serve as anchor residues for binding, reflecting the fact that the MHC I 126 
 
peptide binding pocket is closed on both ends.  As a result, using a similar strategy to 
deliver MHC class I peptides would be more challenging, requiring the use of MMP-
cleavable sequences that are shorter or share redundant amino acids with the peptide 
antigen of interest. 
 
In agreement with the peptide presentation that was observed in vivo, endogenous 
antigen-specific T cells expanded in the draining LNs.  The frequency of tetramer+ T cells 
was significantly increased at day 5, but this population then contracted and returned 
to  near  baseline  levels  by  day  14.    These  kinetics  were  similar  to  what  was  seen  in 
Chapter  3,  when  PLG  particles  were  used  to  deliver  peptide.    An  analysis  of  cells 
isolated  from  the  gels  revealed  that  the  fraction  of  CD4+  cells  was  very  low,  but 
increased to ~7% at day 14.  These results were consistent with those seen previously in 
Chapter 2 when only GM-CSF was delivered, suggesting that the delivery of antigen in 
addition to GM-CSF here did not have a big impact on T cell recruitment to the gels.  
Although few CD4+ T cells were found in the gels, the fraction of those cells that were 
tetramer+ increased markedly over time, reaching a strikingly high level of ~28% at day 
14.    Interestingly,  this  increase  happened  in  the  same  timeframe  over  which  the 
frequency of tetramer+ cells was seen to decrease in the draining LNs.  A more detailed 
analysis of the T cells in the gels at day 14 revealed that the fraction of FoxP3+ cells was 
unusually high, constituting 64% of CD4+ T cells and 62% of the more limited tetramer+ 
subset.  The average number of tetramer+ FoxP3+ cells present in the gels was ~7,000, 
which is on the same order as the number of CD4+ CD25+ BDC2.5 cells that were shown 
to significantly delay disease in NOD mice19. 
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As touched on in Chapter 3, it would be of great interest to determine the fate of the 
antigen-specific T cells that expanded in the draining LNs at day 5, but subsequently 
decreased in frequency at later timepoints.  Given that the increase in antigen-specific 
cells in the  gels occurs at the  same  time  as their  decrease  in the  draining  LNs, it is 
speculated that some of the antigen-specific T cells that expanded in the draining LNs 
could have homed to the gels due to the presence of antigen.  This phenomenon has 
been seen in the materials-based cancer vaccine developed by Ali et al., where tumor 
specific CD8+ T cells are found in the material after 12 days20.  If the same phenomenon 
occurred  in  this  system,  it  raises  the  distinct  possibility  that  some  of  the  expanded 
antigen-specific T cells may have migrated into peripheral tissues and homed to the 
pancreatic islets, where the endogenous antigen is located.  However, changes in the 
frequency of antigen-specific T cells were not seen in the pancreatic LNs, so a direct 
analysis of the pancreatic islets would be needed to confirm this.  Additionally, it would 
be important to confirm that these tetramer+ cells expressing FoxP3 are functional Tregs, 
with  the  ultimate  test  being  the  ability  of  the  material  system  to  prevent  or  reverse 
disease in NOD mice. 
 
   128 
 
4.5 References 
 
1.  Pradeu,  T.,  Jaeger,  S.  &  Vivier,  E.  The  speed  of  change:  towards  a  discontinuity 
theory of immunity? Nat. Rev. Immunol. 13, 764–769 (2013). 
2.  Corse, E., Gottschalk, R. A. & Allison, J. P. Strength of TCR–Peptide/MHC Interactions 
and In Vivo T Cell Responses. J. Immunol. 186, 5039–5045 (2011). 
3.  Turner,  M.  S.,  Kane,  L.  P.  &  Morel,  P.  A.  Dominant  role  of  antigen  dose  in 
CD4+Foxp3+ regulatory T cell induction and expansion. J. Immunol. Baltim. Md 1950 
183, 4895–4903 (2009). 
4.  Long, S. A. et al. Low-dose antigen promotes induction of FOXP3 in human CD4+ T 
cells. J. Immunol. Baltim. Md 1950 187, 3511–3520 (2011). 
5.  Apostolou, I. & Boehmer, H. von. In Vivo Instruction of Suppressor Commitment in 
Naive T Cells. J. Exp. Med. 199, 1401–1408 (2004). 
6.  Gottschalk, R. A., Corse, E. & Allison, J. P. TCR ligand density and affinity determine 
peripheral induction of Foxp3 in vivo. J. Exp. Med. 207, 1701–1711 (2010). 
7.  Daniel,  C.,  Weigmann,  B.,  Bronson,  R.  &  Boehmer,  H.  von.  Prevention  of  type  1 
diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. 
J. Exp. Med. 208, 1501–1510 (2011). 
8.  Murthy, N., Thng, Y. X., Schuck, S., Xu, M. C. & Fréchet, J. M. J. A Novel Strategy for 
Encapsulation and Release of Proteins:  Hydrogels and Microgels with Acid-Labile 
Acetal Cross-Linkers. J. Am. Chem. Soc. 124, 12398–12399 (2002). 
9.  Li,  C.,  Madsen,  J.,  Armes,  S.  P.  &  Lewis,  A.  L.  A  New  Class  of  Biochemically 
Degradable, Stimulus-Responsive Triblock Copolymer Gelators. Angew. Chem. Int. 
Ed. 45, 3510–3513 (2006). 
10.  Page-McCaw,  A.,  Ewald,  A.  J.  &  Werb,  Z.  Matrix  metalloproteinases  and  the 
regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221–233 (2007). 
11.  Ratzinger,  G.  et  al.  Matrix  Metalloproteinases  9  and  2  Are  Necessary  for  the 
Migration of Langerhans Cells and Dermal Dendritic Cells from Human and Murine 
Skin. J. Immunol. 168, 4361–4371 (2002). 
12.  Lutolf, M. P. et al. Repair of bone defects using synthetic mimetics of collagenous 
extracellular matrices. Nat. Biotechnol. 21, 513–518 (2003). 129 
 
13.  Lutolf,  M.  P.  et  al.  Synthetic  matrix  metalloproteinase-sensitive  hydrogels  for  the 
conduction of tissue regeneration: Engineering cell-invasion characteristics.  Proc. 
Natl. Acad. Sci. 100, 5413–5418 (2003). 
14.  Seliktar, D., Zisch, A. H., Lutolf, M. P., Wrana, J. L. & Hubbell, J. A. MMP-2 sensitive, 
VEGF-bearing  bioactive  hydrogels  for  promotion  of  vascular  healing.  J.  Biomed. 
Mater. Res. A 68A, 704–716 (2004). 
15.  Kraehenbuehl, T. P. et al. Human embryonic stem cell-derived microvascular grafts 
for cardiac tissue preservation after myocardial infarction.  Biomaterials 32, 1102–
1109 (2011). 
16.  Patterson,  J.  &  Hubbell,  J.  A.  Enhanced  proteolytic  degradation  of  molecularly 
engineered PEG hydrogels in response to MMP-1 and MMP-2. Biomaterials 31, 7836–
7845 (2010). 
17.  Turk,  B.  E.,  Huang,  L.  L.,  Piro,  E.  T.  &  Cantley,  L.  C.  Determination  of  protease 
cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol. 
19, 661–667 (2001). 
18.  Huebsch, N. et al. Matrix elasticity controls bone formation by transplanted stem 
cells. Rev. 
19.  Tarbell, K. V., Yamazaki, S., Olson, K., Toy, P. & Steinman, R. M. CD25+ CD4+ T cells, 
expanded with dendritic cells presenting a single autoantigenic peptide, suppress 
autoimmune diabetes. J. Exp. Med. 199, 1467–1477 (2004). 
20.  Ali, O. A., Emerich, D., Dranoff, G. & Mooney, D. J. In situ regulation of DC subsets 
and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8ra19 (2009). 130 
 
Chapter 5. Conclusions, Implications and Future Directions 
 
5.1 Conclusions 
 
In this thesis, a new material delivery system was developed to recruit DCs in a non-
inflammatory context and induce specific responses to defined antigens.  Injectable 
alginate-based hydrogels were designed to release GM-CSF in a sustained manner and 
form pores that allowed cell infiltration into the material.  In addition, these materials 
were designed to release a peptide antigen in a highly localized manner for uptake by 
the recruited DCs.  This system was tested in the NOD mouse model of type 1 diabetes 
to examine the ability of the DCs to present the diabetes-related peptide delivered in 
the material system and induce antigen-specific T cell responses. 
 
In Chapter 2, the development of an injectable hydrogel system for recruiting DCs was 
described.  A strategy was developed for the sustained delivery of GM-CSF, which is not 
heparin-binding  at  neutral  pH,  from  alginate.    Gradual  and  sustained  release  was 
achieved by conjugating GM-CSF to AuNP carriers and incorporating it into alginate 
hydrogels in the absence of cystine.  The physical structure of the pore-forming gels was 
also examined to determine the optimal volume fraction and degradation rate for the 
porogens,  which  degrade  and  create  a  macroporous  structure  within  the  bulk 
hydrogels.  This system was able to recruit several million cells into the gels, and closer 
examination revealed that the vast majority of these cells consisted of CD11b+ CD11c+ 
DCs,  which  could  attain  purities  greater  than  90%  at  certain  timepoints.    Increased 131 
 
numbers of total cells and frequencies of CD11c+ cells in the lymph nodes draining the 
gels suggested that the recruited DCs might be migrating to the draining LNs. 
 
Next, in Chapter 3, a  defined peptide  antigen was incorporated into this system to 
allow localized delivery and  presentation by DCs.  PLG microparticles were  used  to 
deliver peptide at a slow and sustained rate.  Localized biodistribution and peptide 
presentation  were  demonstrated.    T  cells  proliferated,  expanded,  and  secreted 
cytokines  in  an  antigen-specific  manner,  primarily  in  the  LNs  draining  the  gel.  
Proliferating T cells were also detected, to a lesser extent, in other LNs, suggesting that 
they are competent to traffic systemically after interacting with DCs in the draining LNs.  
The PLG particles were found to significantly alter the phenotype of the cells present in 
the gels.  Whereas gels delivering only GM-CSF experienced a striking enrichment of 
CD11c+  cells,  this  enrichment  was  impaired  in  gels  delivering  PLG  and  peptide.  
Conversely, the population of Gr-1+ cells, which decreased in inverse proportion to the 
CD11c+  population  in  gels  without  PLG,  remained  high  with  the  addition  of  PLG 
particles.  When gene and protein expression were assayed, the gels containing PLG 
were found to display higher levels of several inflammatory cytokines compared to gels 
without PLG.  Somewhat surprisingly, at the mRNA level, cells from gels both with and 
without  PLG  expressed  lower  relative  levels  of  many  assayed  genes  compared  to 
control splenic DCs.  At the protein level, gels delivering GM-CSF alone were associated 
with low levels of inflammatory cytokines.  In addition, the expression of the negative 
costimulatory molecules PD-L1 and PD-L2 by DCs recruited to gels delivering GM-CSF 
was a promising indication that they may have the capacity to induce tolerogenic 
responses. 132 
 
 
The  observation  that  exposure  to  PLG  altered  the  phenotype  of  recruited  cells 
motivated  the  development  of  a  new  strategy  for  delivering  peptide  in  a  localized 
manner, which was described in Chapter 4.  The goal was to covalently couple the 
peptide to the polymer forming the bulk hydrogel, while still allowing release such that 
the peptide could be loaded and presented on MHCII.  After determining that cell 
infiltration into the gels was associated with increased MMP activity, an MMP-cleavable 
peptide linker was chosen to allow cell-triggered release upon infiltration of DCs into the 
material.    An  MMP-cleavable  sequence  was  added  to  the  N-terminal  end  of  the 
peptide antigen, which was subsequently conjugated to alginate.  This material was 
shown  to  trigger  antigen-specific  T  cell  responses  both  in  vitro  and  in  vivo,  and  an 
accumulation of tetramer+ FoxP3+ T cells was observed in the gels.  A study to evaluate 
the impact of this material system on disease progression was underway at the time this 
dissertation  was  written,  and  no  acceleration  in  disease  progression  was  observed 
following  the  administration  of  three  doses  of  peptide  loaded  gels  (Appendix  D).  
Approximately 10 weeks after the first gel administration, 70% of the mice that received 
peptide-loaded gels remained diabetes free, while only 40% of the mice in the control 
group were diabetes free, but the difference in the disease progression curves were not 
statistically significantly different at this timepoint. 
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5.2 Implications 
 
This work has advanced the area of immunomodulatory biomaterials in three important 
areas. 
 
The  material  system  described  here  achieved  an  enrichment  of  DCs  that  was 
unprecedented  in  terms  of  the  high  purity  of  CD11b+  CD11c+  cells  recruited.    This 
property could be useful to develop materials-based vaccines, either for tolerance or 
immunity, that have the capacity to manipulate a highly enriched population of DCs, 
potentially allowing more precise and potent control over the downstream responses. 
 
Further, a detailed characterization of this material system revealed that the recruited 
DCs can be qualified as immature based on cell surface marker expression as well as 
cytokine expression at the mRNA and protein levels.  The goals of effectively recruiting 
DCs  while  preventing  their  maturation  are  inherently  somewhat  at  odds,  but  the 
strategy employed here fulfilled both goals.  Immature or semi-mature DCs are present 
in  steady  state  conditions  in  vivo,  but  this  system  presents  an  opportunity  to 
concentrate a greater number of such DCs in one location. 
 
Finally,  this  work  advanced  the  methodology  for  delivering  peptide  antigens  from 
biomaterials.    It  was  shown  that  a  defined  peptide  antigen  could  be  covalently 
coupled to the material system and released in a cell-triggered manner, allowing it to 
remain highly localized while still retaining the capacity to be functionally presented by 
DCs  to  T  cells.    This  advance  has  important  implications  for  improving  the  safety  of 134 
 
tolerogenic therapies that involve  the  administration of disease-related  self-antigens, 
since  it  provides  a  strategy  to  prevent  the  dissemination  of  antigens  to  a  site  of 
inflammation and disease, while still making those antigens accessible to the immune 
system in a non-inflammatory environment. 
 
5.3 Future Directions 
 
In  this  thesis,  significant  steps  were  taken  towards  the  development  of  a  materials-
based  system  that  induces  antigen-specific  tolerogenic  responses,  but  a  large 
parameter space remains to be explored to achieve robust and long-lasting tolerance 
that is effective in a therapeutic setting.  In the process, a great deal stands to be 
learned about the immunological mechanisms controlling tolerance versus immunity. 
 
The dose, delivery kinetics, and sequences of the delivered peptide antigens may have 
profound  effects  on  the  outcome  of  the  immune  response.    The  use  of  a  material 
system such as the one described here allows these parameters to be tested in greater 
detail than would be possible otherwise.  The effect of peptide delivery on downstream 
immune  responses  can  be  explored  not  only  by  modifying  the  dose  of  delivered 
peptide,  but  also  by  tuning  the  sequence  of  the  MMP  cleavable  linker  to  achieve 
different cell-triggered release kinetics.  In addition, different peptide antigens will exert 
different effects on the induction of tolerance.  Even among peptide mimetopes that 
are  recognized  by  the  same  TCR,  some  may  be  more  effective  at  inducing  or 
expanding Tregs, while others may induce anergy or deletion of self-reactive effector T 
cells.    Studies  have  shown  that  high-affinity  peptide  mimetopes  may  be  more 135 
 
appropriate for inducing tolerance, since they have an increased capacity to induce 
conversion of FoxP3+ Tregs, thus preventing disease in a mouse model T1D1.  In light of 
these findings, the selection of appropriate peptide antigens should be considered and 
tested in the design of materials-based vaccines, and it may be of great interest to 
incorporate more than one peptide into the system.  For instance, delivering several 
peptides  with  different  binding  affinities  for  the  same  cognate  TCR  could  induce 
tolerance through multiple mechanisms, i.e. induction of anergy, deletion, as well as 
expansion and activation of Tregs.  Alternatively, it may be useful to incorporate several 
peptides  derived  from  different  antigens  to  induce  Tregs  with  multiple  antigen 
specificities, which may afford more potent disease suppression.  The material system 
described here could provide a useful platform to test such hypotheses. 
 
The  localized  delivery  of  peptide  also  represents  a  great  opportunity  to  control  the 
context in which DCs encounter an antigen by creating a microenvironment that is not 
only non-inflammatory, but also provides tolerogenic signals.  The delivery of different 
types  and  doses  of  soluble  tolerogenic  factors  may  be  explored  to  induce  a  more 
robust tolerogenic DC phenotype.  In addition, since this system mediates infiltration of 
cells within the material, it could provide an ideal platform for incorporating insoluble 
immunomodulatory cues in the form of tethered antibodies or binding motifs derived 
from receptors or ECM components.  For instance, the material could be modified to 
provide  negative  costimulatory  signaling  to  cells  by  conjugating  it  to  activating 
antibodies  or  extracellular  domains  of  receptors,  such  as  CTLA4-Ig  or  PD-L1/2-Ig.  
Another interesting line of research has shown that certain ECM proteins can act as 
tissue  integrity  signals,  as  in  the  case  of  hyaluronic  acid  (HA),  which  was  shown  to 136 
 
enhance the function of Tregs3,4 and induce Tr1 cells5 in its high molecular weight form, 
while its low molecular weight form is an indicator of tissue damage and does not exert 
tolerogenic effects.  These findings may be readily applied to enhance this alginate-
based material system by decorating the polymer with multivalent signaling motifs to 
mimic the effects of HMW HA, such as activating anti-CD44 or HA binding sites, in such 
a way that they cannot be degraded into LMW forms by endogenous enzymes.  Finally, 
modulating physical properties such as the stiffness or viscoelasticity of the material may 
also have an impact on DC maturation or antigen uptake, as well as on the recruitment 
and function of other immune cells. 
 
Finally,  this  platform may  be  used  more  broadly  to  recruit  and  manipulate  different 
immune  cell  types,  other  than  DCs.    It  is  speculated  that  this  material  acts  as  a 
privileged site for the infiltration of immune cells, partly due to the intentional lack of cell 
adhesion ligands on the alginate polymer.  This property could be used to recruit one or 
more different immune cell populations by delivering different cytokines or chemokines.  
In the area of immune tolerance, several different bioactive factors have been shown 
to act on both DCs and T cells, such as IL-10, TGF-b1, or the small molecule AHR ligand 
ITE6.  It may be possible to take full advantage of these tolerogenic factors and achieve 
enhanced priming of tolerogenic responses at the site of the material by recruiting DCs 
together with naïve T cells, which migrate in response to CCL19 or CCL21.  This material 
system could also serve as a useful model to study the interplay between other innate 
or adaptive immune cell types, such as B cells, macrophages, or NK cells, in an in vivo 
setting. 
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Future work will evaluate the feasibility of these ideas, which represent exciting avenues 
for  investigating  important  questions  in  immunology  and  for  advancing  the 
development of novel immunomodulatory therapies. 
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Appendices.  Preliminary Studies for Future Work and Detailed Protocols 
 
Appendix A.  Theoretical packing of spherical proteins on AuNPs. 
 
A.1 Method 
 
The amount of GM-CSF to be conjugated to AuNPs was determined by calculating the 
theoretical packing of GM-CSF molecules on the surface of the AuNPs.  The diameter of 
GM-CSF was estimated based on its molecular weight, with the assumption that GM-
CSF is a globular protein.  Synthesized AuNPs were analyzed by DLS to measure their 
diameter, and their concentration was determined based on their absorbance at 518-
519nm.    AuNPs  and  GM-CSF  were  modeled  as  spheres  (Fig.  A.1  A),  and  simple 
geometry  was  used  to  determine  the  separation  angle  theta  (θ)  between  two 
adjacent small spheres (GM-CSF) contacting a larger sphere (AuNP) at one point (Fig. 
A.1 B).  This angle θ can be looked up in tables of spherical codes1 to determine the 
most efficient theoretical packing of GM-CSF molecules onto AuNPs.  A 50% excess of 
protein was used to ensure that the AuNPs are fully coated. 
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A          B       
     
Figure A.1. Protein packing on AuNPs was modeled as packing of spheres.  (A) Diagram 
of  GM-CSF  and  AuNPs  modeled  as  spheres.    (B)  Geometry  used  to  determine  the 
separation angle theta between two adjacent small spheres sitting on the surface of a 
larger sphere.  (Adapted from Weisstein). 
 
A.2 References 
1.  Weisstein,  E.  W.  Spherical  Code  --  from  Wolfram  MathWorld.  at 
<http://mathworld.wolfram.com/SphericalCode.html> 
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Appendix B.  Flow cytometry reagents. 
 
 
Table B.1.  Staining antibodies, tetramers, and other reagents used for flow cytometry. 
Antigen  Clone  Fluorophore  Vendor 
CD11b  M1/70  APC-Cy7 or APC-eFluor780 eBioscience or BioLegend 
CD11c  N418  Alexa 488 or APC  eBioscience 
F4/80  BM8  PE-Cy7  BioLegend 
Gr-1  RB6-8C5  Pacific Blue  BioLegend 
DX5 (CD49b)  DX5  PE  BioLegend 
CD3e  145-2C11  PE-Cy7  BioLegend 
CD4  RM4-5 or GK1.5 Pacific Blue or FITC  eBioscience or BioLegend 
CD8a  53-6.7  Alexa 488 or PE  eBioscience 
CD25  PC61  FITC or APC  BioLegend 
MHC II (I-A/I-E)  M5/114.15.2  Pacific Blue  BioLegend 
CD86  PO3  APC  BioLegend 
CCR7 (CD197)  4B12  PE  BioLegend 
PD-L1 (CD274)  10F.9G2  Brilliant Violet 421  BioLegend 
PD-L2 (CD273)  TY25  PE  BioLegend 
PDCA-1  CD317  PE-Cy7  BioLegend 
CD207  4C7  PE  BioLegend 
CD205  NLDC-145  PE-Cy7  BioLegend 
CD103  2E7  Pacific Blue  BioLegend 
FoxP3  FJK-16s  PE  eBioscience 
 
     
Tetramer (MHCII I-Ag7)   PE or APC  NIH Tetramer Core 
 
     
7-AAD viability dye     BioLegend 
Fc Block (CD16/CD32)  93 -  eBioscience or BioLegend 
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Appendix C.  Representative flow cytometry plots. 
 
 
 
A             B                  C 
                  
 
 
D             E                  F 
                   
 
 
Figure C.1. Flow cytometry plots for cells isolated from gels delivering GM-CSF + AuNP 
after 5 days.  (A-C) CD11b (x-axis) plotted against F4/80 (A), Gr-1 (B), and DX5 (C). (D-F) 
CD11c (x-axis) plotted against CD86 (D), MHCII (E), and CCR7 (F).   
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Appendix D.  Preliminary disease study in the NOD model of type 1 diabetes. 
 
The safety of the material system described in this thesis, as well as its impact on disease 
progression,  were  evaluated  in  the  NOD  mouse  model  of  type  1  diabetes.    Gels 
delivering  GM-CSF  and  BDC-CMR  peptide-modified  alginate  were  administered  at 
intervals of 25 days.  Tolerogenic factors were also included to evaluate whether they 
could  provide  any  added  protection  from  disease.    Three  administrations  of  this 
material delivery system did not result in any acceleration of disease progression.  At the 
time of writing, 40% of the mice in the control and TGF-β1 groups were diabetes free, 
while 70% of the mice in the gel and gel + dex groups remained diabetes free.  The 
curves  were  not  statistically  significantly  different.    It  will  be  of  great  interest  to 
determine whether a protective effect will be seen in the gel or gel + dex conditions. 
 
 
Figure D.1.  Effect of the material delivery system on disease progression in NOD mice.  
Three  doses  of  gels  delivering  GM-CSF  and  0.1nmol  of  BDC  peptide  conjugated  to 
alginate were injected subcutaneously into the flanks of female NOD/ShiLtJ mice at 
intervals between 7 and 13 weeks.  For two of the groups, either dexamethasone (dex) 
or TGF-  β1 + IL10 were co-delivered in the gels. Naïve mice did not receive any gel 
injections.    Blood  glucose  measurements  were  taken  twice  weekly,  and  mice  were 
considered  diabetic after two consecutive non-fasting blood glucose  readings >250 
mg/dL.  (n=10). 144 
 
Appendix  E.    VEGF  abrogates  the  efficacy  of  a  DC  programming  materials-
based cancer vaccine. 
 
E.1 Introduction 
 
The expression of VEGF by growing tumors and its role in tumor angiogenesis has been 
extensively  characterized.    Anti-VEGF  therapies  are  now  used  in  the  clinic  to  limit 
angiogenesis and normalize the tumor vasculature1, leading to improved outcomes.  
More  recently,  it  was found  that,  in  addition  to  enhancing angiogenesis,  VEGF  also 
exerts other effects by acting on tumor cells themselves, as well as on tumor-infiltrating 
immune cells1.  There is increasing evidence that VEGF contributes to establishing an 
immunosuppressive environment in tumors through a number of mechanisms, including 
inducing  myeloid-derived  suppressor  cells  (MDSCs),  recruiting  immature  DCs, 
suppressing DC maturation1, and promoting FoxP3+ Treg infiltration2.  Previously Ali et al. 
developed  a  materials-based  cancer  vaccine  that  was  found  to  be  effective  at 
improving survival in a mouse model of melanoma3.  This same material system has also 
been used to deliver VEGF in vivo in the setting of ischemia4.  Here, this implantable 
material was used as a platform to combine VEGF delivery together with the cancer 
vaccine and investigate the effects of VEGF on the priming of anti-tumor immunity. 
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E.2 Materials and Methods 
 
PLG microsphere fabrication 
Peptide-loaded PLG microspheres were fabricated following the procedure described 
in Chapter 2. 
 
Vaccine fabrication and implantation 
PLG scaffold based vaccines containing 3ug GM-CSF, 100ug CpG, and lysate from B16 
tumors were fabricated and implanted subcutaneously into the flanks of C57BL/6J mice 
as described previously3. 
 
Tumor growth assays 
105 B16-F10 melanoma cells were injected subcutaneously into the back of the necks of 
C57BL/6J mice.  Tumor growth was monitored by measuring the length and width of the 
tumors using calipers.  Mice were euthanized according to humane endpoints. 
 
Cytokine analysis 
Cytokine analysis was performed as described in Chapter 3. 
 
E.3 Results 
 
When 3ug of  VEGF were added to the fully functional PLG scaffold-based vaccine, 
vaccine  efficacy  was  completely  abrogated  in  both  therapeutic  (Fig.  E.1  A)  and 
prophylactic (Fig. E.1 B) treatment modalities.  In the setting of therapeutic vaccination, 146 
 
mice that received the standard vaccine exhibited prolonged survival compared to 
the unvaccinated controls, but the mice that received vaccine + VEGF did not.  In the 
case  of  prophylactic  vaccination,  the  standard  vaccine  allowed  90%  survival  after 
tumor challenge, whereas the addition of VEGF to the vaccine led to 0% survival.  The 
tumor growth curves from the prophylactic vaccination study were analyzed in greater 
detail by fitting exponential curves to the experimental data.  The tumor growth rate, as 
indicated by the doubling time, was the same for the unvaccinated controls and the 
mice  that  received  Vaccine  +  VEGF.    However,  the  time  to  tumor  initiation  was 
statistically  significantly  shorter  for  the  vaccine  +  VEGF  condition  compared  to  the 
control condition.  When the scaffolds were analyzed for cytokines, it was found that 
the scaffolds with added VEGF contained a significantly higher concentration of IL-10 
protein than the standard vaccine. 
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Figure E.1.   148 
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Figure E.1 (continued).  Incorporation of VEGF abrogated the efficacy of a materials-
based    cancer  vaccine  in  a  model  of  melanoma.  (A)  Survival  of  mice  that  were 
vaccinated 9 days after being inoculated with B16 tumors.  (n = 9-10; ** p < 0.01).  (B) 
Survival of mice that were prophylactically vaccinated and challenged with B16-F10 
tumor cells 14 days later.  (n = 7-9; *** p < 0.001).  (C) Individual tumor growth curves 
from the prophylactic study shown in (B).  (D) Tumor doubling times for unvaccinated 
controls  or  mice  that  were  vaccinated  with  scaffolds  containing  VEGF  in  the 
prophylactic  study.    (n  =  7-9;  mean  ±  s.d.  shown).    (E)  Time  until  formation  of  a 
macroscopic tumor in controls or mice that received vaccines containing VEGF.  (n = 7-
9; mean ± s.d. shown; * p < 0.05).  (F) IL-10 concentration in scaffolds 10 days after 
implantation.  (n = 5; mean ± s.d. shown; ** p < 0.01).   149 
 
E.4 Discussion 
 
The addition of VEGF to a functional materials-based cancer vaccine had the striking 
effect of completely abrogating vaccine efficacy.  Based on previous studies analyzing 
the spatio-temporal presentation of VEGF from PLG scaffolds, the VEGF delivered in the 
scaffold vaccines was not expected to reach the tumor site.  This is consistent with the 
fact that the presence of VEGF in the vaccines did not affect the growth rate of the 
tumors.  Interestingly, in the setting of prophylactic vaccination, tumors growth initiated 
earlier in  mice  that  received vaccines containing  VEGF  compared  to  controls.    This 
finding suggests that the vaccines containing VEGF may mediate the development of 
tolerance towards tumor antigens, allowing tumors to emerge sooner.  The fact that a 
higher concentration of IL-10 was detected in vaccines containing VEGF supports the 
notion that a more tolerogenic environment in those scaffolds may be responsible for 
impairing the efficacy of the vaccine.  These results warrant further investigation and 
may hold important implications for the design of materials-based cancer vaccines. 
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Appendix F.  Labeling cells to track DC migration in vivo 
 
F.1 Introduction 
 
Biomaterials are increasingly being used to recruit and program cells in vivo for a variety 
of applications, such as immune modulation1 or tissue regeneration2.  Consequently, it is 
of great interest to be able to identify and track cells in vivo that came into contact 
with a biomaterial and subsequently migrated to a different location.  In the field of 
immunology, fluorescein isothiocyanate (FITC) has been used to “paint” the skin and 
identify DCs that migrated from the skin into the lymph nodes.  In an analogous manner, 
FITC  was  also  used  by  Ali  et  al.  to  “paint”  PLG  scaffolds  and  track  DCs  that  were 
recruited into the scaffolds in vivo and then redeployed into the draining lymph nodes1.  
While  this  technique  is  useful,  it  may  still  be  improved,  since  FITC  is  not  as  bright  or 
persistent  as  some  other  cell  tracking  dyes.    Here,  the  cell  tracking  dyes 
carboxyfluorescein diacetate succinimidyl ester (CFSE) and CellTrace Violet (CTV) were 
tested for their ability efficiently and specifically labeling of cells that come into contact 
with a biomaterial without negatively impacting cell viability or function. 
 
F.2 Materials and Methods 
 
PLG microsphere fabrication 
Peptide-loaded PLG microspheres were fabricated following the procedure described 
in Chapter 2.  5 nmol of CFSE (eBioscience) or CTV (Life Technologies) in DMSO were 
added per 1.5mg of PLG particles. 152 
 
 
BMDC labeling assay 
Bone  marrow  was  isolated  from  C57BL/6J  mice  and  BMDCs  were  differentiated  as 
described in Chapter 3.  For C57BL/6J BMDCs, the initial plating density was 2 x 106 cells 
in 10mL of medium.  After 6 days of differentiation, BMDCs were collected and plated in 
12 well tissue culture treated plates at a density of 106 cells / well.  1.5 mg of dye-loaded 
PLG  microspheres  were  incubated  directly  with  the  cells  or  added  to  the  top 
compartment of transwell inserts with 1um pores (Greiner).  A total of 2mL of medium 
was added to each well.  For wells containing transwell inserts, appropriate volumes of 
medium  were  added  inside  (0.6mL)  and  outside  (1.4mL)  the  transwell  to  avoid 
differences in hydrostatic pressure. 
 
Flow cytometry 
Flow cytometry was performed as described in Chapter 2. 
 
F.3 Results 
 
Cells  that  were  incubated  directly  with  dye-loaded  PLG  particles  were  efficiently 
labeled  using  either  CFSE  or  CTV  (Fig.  F.1  A-B).    On  the  other  hand,  when  the  PLG 
particles were added to the upper compartment of transwell inserts, little to no cell 
labeling  was  observed  (Fig.  F.1  A-B).    This  method  for  labeling  DCs  did  not  have  a 
significant impact on their viability or CD11c expression (Fig. F.1 C-D). 
 
   153 
 
 
 
A          B 
   
       
C          D 
   
 
        
Figure  F.1.    PLG  particles  loaded  with  cell  tracking  dyes  effectively  labeled  BMDCs.  
BMDCs were incubated for 6 days either directly with dye-loaded particles, or in wells 
that contained dye-loaded particles in the top compartment of a transwell insert.  (A-B) 
Labeling of BMDCs with CFSE (A) or CTV (B).  (C-D) CD11c expression by DCs labeled 
with CFSE(C) or CTV (D).   
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F.4 Conclusion 
 
The  cell tracking  dyes CFSE and CTV, were  shown to effectively label BMDCs when 
delivered from PLG.  The dye-loaded particles did not lead to labeling of cells that they 
did  not  contact  directly,  which  may  be  explained  by  the  fact  that  they  are 
hydrophobic and do not diffuse significantly out of the PLG.  The CFSE and CTV dyes, 
which  are  commonly  used  to  label  cells  ex  vivo  for  cell  tracking  or  proliferation 
experiments, may also prove to be highly useful for achieving direct in vivo labeling of 
cells that come into contact with a biomaterial.  Since these dyes are brighter and 
longer lasting than FITC, it may be possible to achieve more sensitive and accurate 
tracking of cells that infiltrate a biomaterial and are subsequently redeployed. 
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